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THE ROLE OF PLATELETS IN OVARIAN CARCINOMA 
Publication No._____ 
Rebecca Lynn Stone, M.D. 
Supervisory Professor:  Anil K. Sood, M.D. 
Background:  Platelets represent one of the largest storage pools of angiogenic and 
oncogenic growth factors in the human body. The observation that thrombocytosis 
(platelet count >450,000/µL) occurs in patients with solid malignancies was made 
over 100 years ago. However, the clinical and biological implications as well as the 
underlying mechanism of paraneoplastic thrombocytosis associated with ovarian 
carcinoma remains unknown and were the focus of the current study.      
Materials and Methods:  Following IRB approval, patient data were collected on 619 
patients from 4 U.S. centers and used to test associations between platelet count at 
initial diagnosis, clinicopathologic factors, and outcome. In vitro effects of plasma-
purified platelets on ovarian cancer cell proliferation, docetaxel-induced apoptosis, 
and migration were evaluated using BrdU-PI flow cytometric and two-chamber 
chemotaxis assays.  In vivo effects of platelet depletion on tumor growth, 
proliferation, apoptosis, and angiogenesis were examined using an anti-platelet 
antibody (anti-mouse glycoprotein 1bα, Emfret) to reduce platelets by 50%.  
Complete blood counts and number of mature megakaryocytes in the spleen and 
bone marrow were compared between control mice and ovarian cancer-bearing 
mice.  Plasma levels of key megakaryo- and thrombopoietic factors including 
thrombopoietin (TPO), IL-1α, IL-3, IL-4, IL-6, IL-11, G-CSF, GM-CSF, stem cell 
factor, and FLT-3 ligand were assayed in a subset of 150 patients at the time of 
initial diagnosis with advanced stage, high grade epithelial ovarian cancer using 
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immunobead-based cytokine profiling coupled with the Luminex® xMAP platform.  
Plasma cytokines significantly associated with thrombocytosis in ovarian cancer 
patients were subsequently evaluated in mouse models of ovarian cancer using 
ELISA immunoassays.  The results of human and mouse plasma cytokine profiling 
were used to inform subsequent in vivo studies evaluating the effect of siRNA-
induced silencing of select megakaryo- and thrombopoietic cytokines on 
paraneoplastic thrombocytosis.    
Results:  Thirty-one percent of patients had thrombocytosis at initial diagnosis.  
Compared to patients with normal platelet counts, women with thrombocytosis were 
significantly more likely to have advanced stage disease (p<0.001) and poor 
median progression-free (0.94 vs 1.35 years, p<0.001) and overall survival (2.62 vs 
4.65 years, p<0.001).  On multivariate analysis, thrombocytosis remained an 
independent predictor of decreased overall survival.  Our analysis revealed that 
thrombocytosis significantly increases the risk of VTE in ovarian cancer patients and 
that thrombocytosis is an independent predictor of increased mortality in women 
who do develop a blood clot.  Platelets increased ovarian cancer cell proliferation 
and migration by 4.1- and 2.8-fold (p<0.01), respectively. Platelets reduced 
docetaxel-induced apoptosis in ovarian cancer cells by 2-fold (p<0.001).  In vivo, 
platelet depletion reduced tumor growth by 50%.  Staining of in vivo specimens 
revealed decreased tumor cell proliferation (p<0.001) and increased tumor and 
endothelial cell apoptosis (p<0.01). Platelet depletion also significantly decreased 
microvessel density and pericyte coverage (p<0.001).  Platelet counts increase by 
31-130% in mice with invasive ovarian cancer compared to controls (p<0.01) and 
strongly correlate with mean megakaryocyte counts in the spleen and bone marrow 
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(r=0.95, p<0.05).  Plasma levels of TPO, IL-6, and G-CSF were significantly 
increased in ovarian cancer patients with thrombocytosis.  Plasma levels of the 
same cytokines were found to be significantly elevated in orthotopic mouse models 
of ovarian cancer, which consistently develop paraneoplastic thromocytosis.  
Silencing TPO, IL-6, and G-CSF significantly abrogated paraneoplastic 
thrombocytosis in vivo.      
Conclusions:  This study provides new understanding of the clinical and biological 
significance of paraneoplastic thrombocytosis in ovarian cancer and uncovers key 
humoral factors driving this process.  Blocking the development of paraneoplastic 
thrombocytosis and interfering with platelet-cancer cell interactions could represent 
novel therapeutic strategies.       
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Background and Introduction 
 
Human epithelial ovarian cancer 
      Epithelial ovarian cancer is the fifth leading cause of cancer death among 
women and is the most lethal gynecological malignancy.  An estimated 21,000 
women are diagnosed with and 15,000 women die from this disease annually (1).  
While disease-specific mortality has changed minimally, median survival time for 
women with advanced ovarian cancer has consistently improved, corresponding to 
a 1.6 year gain in life expectancy between 1973 and 2000 (2).  The negligible 
increase in cure rates over the past 30 years is multi-factorial.  Principally, disease 
onset is insidious with most women experiencing vague symptoms that often evade 
early clinical detection.  Further, no sufficiently accurate screening test is currently 
available even for women at increased genetic risk for ovarian cancer.   These two 
factors largely contribute to advanced disease at the time of diagnosis (3).  The 
standard of care for ovarian cancer involves tumor reductive surgery followed by 6 
cycles of platinum/taxane based chemotherapy (4).  Fortunately, epithelial ovarian 
cancer is among the most chemosensitive malignancies, with an initial 70-80% 
response rate to combination platinum/taxane chemotherapy (5).  Unfortunately, the 
vast majority of patients develop recurrent ovarian cancer and eventually succumb 
to their disease.  First-line chemotherapy fails in more than 20 percent of patients 
with epithelial ovarian cancer and approximately 40 to 50 percent of women who 
respond to initial treatment relapse within 2 years.  In the setting of recurrent, 
platinum resistant ovarian cancer, second line cytotoxic agents have a 15 to 20 
percent response rate with virtually no cures (6-8).  Clinical studies published over 
the past 15 years, including Gynecologic Oncology Group (GOG) 111, GOG 132, 
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and International Collaborative Ovarian Neoplasm (ICON) 3 trials, report an 11 to 
18 month median progression-free survival and a 24 to 40 month median overall 
survival for women with epithelial ovarian cancer depending on the stage and extent 
of surgical cytoreduction (9-11).  This poor prognosis implores development of more 
efficacious therapeutic options for women with epithelial ovarian cancer, both in 
first-line and relapsed disease settings.  While new developments in surgery and 
chemotherapy have advanced the field, recent studies suggest that the addition of 
more cytotoxic drugs to the current standard of platinum/paclitaxel is unlikely to 
result in substantial improvements in clinical outcome.  Recently, GOG 182/ICON5 
trial demonstrated that the addition of gemcitabine, liposomal doxorubicin, or 
topotecan to paclitaxel and carboplatin provides no additional benefit (12).  
Fortunately, clinical investigations currently evaluating the efficacy of therapies that 
specifically target biological processes driving the growth and progression of 
ovarian cancer are showing promising results.  Anti-VEGF agents that inhibit tumor 
angiogenesis, such as bevacizumab, illustrate the potential advantage of this 
approach.  Response rates to single agent bevacizumab as second- line therapy for 
ovarian cancer range from 16-21%, which approximates the clinical benefit derived 
from other approved second-line cytotoxic agents such as topotecan (13.7-20.5%) 
and gemcitabine (15-20%) (13-15).  This sets new precedent for exploring the role 
of host factors in promoting malignancy and for developing therapeutic strategies 
based on undermining fundamental host-tumor interactions.  
Vascular thromboembolism in ovarian cancer  
      Most women with ovarian cancer present with advanced disease and suffer a 
variety of complications, including vascular thromoembolism (VTE), during extended 
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treatment courses entailing one or more surgeries and several lines of 
chemotherapy.  VTE is often the sentinel event that leads to a new diagnosis of 
occult ovarian cancer in many of these patients.   A recently published, large 
population-based study found that the incidence of VTE was nearly three times 
higher in the year preceding ovarian cancer diagnosis (16).  Vascular 
thromboembolism complicates the treatment course of up to 25% of ovarian cancer 
patients and is a poor prognostic factor (Table 1) (17, 18).   
 
   Table 1.  Incidence, timing, predictors, and prognostic implications of VTE in 
   ovarian cancer patients 
events/total #  
(%) 
Timing associated 
factors* 
impact on 
survival 
Reference 
18/72 
(25%) 
all cases at time of dx clear cell 
histology* 
massive ascites* 
not examined (19) 
19/86 
(22%) 
at diagnosis: 6  (31%) 
perioperative: 6 (32%) 
during long-term f/u: 7  (37%) 
stage not examined (20) 
42/253  
(16.6%) 
at diagnosis:  8 (19%) 
perioperative: 6 (14.3%) 
during initial treatment: 16 (38.1%) 
during long-term f/u:  12 (28.6%)   
prior event 
age 
stage 
suboptimal TRS* 
BMI* 
not examined (21) 
57/559  
(10%) 
all cases perioperative stage 
ascites 
suboptimal TRS 
no impact (22) 
672/13,031 
(5.2%) 
perioperative:  257 (38.2%) age* 
stage* 
reduced (23) 
76/2,743 
(2.8%) 
preoperative & during initial rx:  
38 (50%) 
age* 
BMI > 30 kg/m2* 
reduced (24) 
128/12,835  
(1%) 
all cases predated diagnosis of 
ovarian cancer 
stage reduced (25) 
   * in multivariate analysis 
 
Taking prevalence into account, cancers of the pancreas, ovary, and brain are the 
most strongly associated with thrombotic complications (26).  The association 
between VTE and underlying cancer is well established.  The connection was first 
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made in the early 19th century by the French clinician Armand Trousseau, who 
observed that patients presenting with idiopathic VTE frequently have an underlying 
visceral malignancy (27).  In 1845, the functional triad mediating the pathogenesis 
of thrombosis was described by pathologist Rudolf Virchow and subsequently 
became known as “Virchow’s triad,” which includes vascular endothelial 
injury/dysfunction, stasis, and hypercoagulability.  Direct injury to the vessel wall 
can be inflicted by extrinsic factors such as chemotherapy (28).  The specific 
mechanism of chemotherapy-induced thrombosis may be related to decreased 
protein C, increased fibrinopeptide A production, increased endothelial cell 
reactivity, release of tissue factor from monocytes and endothelial cells, down 
regulation of thrombomodulin, and decreased fibrinolytic response (21).   Large 
tumor burden and/or massive ascites characteristic of ovarian cancer may 
predispose to VTE by compressing intrapelvic veins and inducing venous stasis.  
Large volume ascites may also be indicative of increased blood viscosity because 
the accumulation of ascites represents a profound redistribution of body fluid from 
the intravascular to the interstitial compartment.  Additionally, venous stasis is an 
inevitable risk in ovarian cancer patients undergoing surgery secondary to 
prolonged operative time and a protracted postoperative course.  Further, there is 
accumulating evidence that cancer in general, and ovarian cancer in particular, are 
exceptionally hypercoagulable states.  A multitude of coagulation pathway proteins 
are increased in ovarian cancer including factor II (thrombin), thrombin receptor 
(protease-activated receptors), factor I (fibrinogen), factor III (tissue factor), fibrin, 
and factors VII, VIII and X (29).  Increased numbers and reactivity of circulating 
platelets also significantly contributes to heightened systemic coagulation activation 
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in ovarian cancer patients.  While there have been numerous investigations 
evaluating the contribution of the aforementioned risk factors for VTE in ovarian 
cancer patients, no studies have defined the role of thrombocytosis.    
Platelets and malignancy 
      Platelets are small anucleate cell fragments derived from megakaryocytes in the 
bone marrow and are highly reactive cellular effectors of hemostasis, inflammation, 
and immunity.  As such, they represent one of the largest reservoirs of angiogenic 
and oncogenic growth factors in the human body.  The concept that platelets might 
play key roles in invasive tumor growth and metastasis is longstanding.  In fact, the 
clinical observation that thrombocytosis (platelet count >450,000/uL according to 
the National Heart, Lung, and Blood Institute, NHLBI) occurs in patients with solid 
malignancies was made over 100 years ago (27).  Nearly 40% of individuals 
incidentally found to have platelet counts exceeding 400,000/µL have an occult 
malignancy; most commonly a gastrointestinal, lung, breast, or ovarian primary (30).  
There is also existing evidence that experimentally induced thrombocytopenia and 
anti-platelet treatment decreases metastasis in various tumor models.  For example, 
platelet-deficient mice due to knockout of NF-E2, a transcription factor required for 
the production of platelets from megakaryocytes, are protected against 
hematogenous metastasis (31, 32).  Additionally, platelet depletion using anti-
platelet serum reduces colon cancer lung metastases, which can be restored by re-
infusing human or mouse platelets (33).  Several possible mechanisms could 
account for platelet induced growth and dissemination of malignancy.  Platelet 
adherence to tumor cells may help tumor cells lodge in the microvasculature where 
they may form intravascular colonies or extravasate into target organs.  Platelet 
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adherence may also shield tumor cells from immune surveillance.  Factors released 
by platelets may support tumor cell survival, proliferation, and invasion.  
Additionally, platelets may release pro-angiogenic factors that stabilize the tumor 
vasculature.  The platelet membrane contains a dense layer of glycoproteins, 
integrins, and selectins which mediate platelet adhesion and aggregation.  Platelet 
adherence to tumor cells is mediated by these receptors and blocking them 
decreases in vivo experimental pulmonary metastasis, increases tumor cell 
interaction with monocytes, and increases tumor cell lysis by natural killer cells (34, 
35).  Activated platelets release numerous bioactive molecules including 
chemokines, cytokines, growth factors, coagulation factors, and metalloproteinases 
from 3 types of secretory vesicles: alpha granules, dense granules and lysosomes.  
In particular, platelet alpha granules are a rich source of both pro- and anti-
angiogenic factors (Table 2).  Recent evidence suggests that pro- and anti-
angiogenic factors are differentially packaged into distinct subpopulations of alpha 
granules that can be selectively deployed by platelets upon engagement of specific 
surface receptors, such as protease-activated receptors (36).   
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   Table 2. Platelet secretory granule content 
α-granules  
pro-angiogenic 
α-granules 
anti-angiogenic 
 vascular endothelial 
growth factor 
thrombospondin 1 
platelet-derived 
growth factor 
platelet factor 4 
basic fibroblast 
growth factor 
plasminogen activator 
inhibitor 1 
epidermal growth 
factor 
endostatin 
transforming growth 
factor 
angiostatin 
insulin-like growth 
factor 
Dense 
granules  
angiopoietin-1 serotonin 
sphingosine-1-
phosphate 
catecholamines 
matrix 
metalloproteinases 
adenosine 
glycoproteins calcium   
ADP/ATP 
p-selectin histamine 
fibrinogen Lysosomes 
von willibrand factor proteinases  
glycosidases 
 
     In addition to the paracrine effects of platelet growth factors, there is evidence for 
a direct role for platelets in stimulating angiogenesis.  Platelet remnants and 
microparticles are found at sites of angiogenic sprouts and in vitro data demonstrate 
a clear dose-response relationship between platelet count and the extent of 
sprouting angiogenesis (37).  Platelets promote the migration and adherence of 
bone-marrow derived cells to sites of angiogenesis and induce differentiation of 
endothelial-cell progenitors into mature endothelial cells (38).  Moreover, activated 
platelets are critical regulators of tumor vascular homeostasis by preventing tumor 
hemorrhage through selective unloading of their granule content (39).  This is a 
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particularly important contribution to the tumor microenvironment given that cancer 
angiogenesis is characterized by morphologically abnormal, immature, dilated and 
leaky blood vessels (40). 
Physiologic mechanisms of megakaryopoiesis and thrombopoiesis 
      Given that the average lifespan of a circulating platelet is only 10 days, the adult 
human must produce approximately one hundred billion platelets daily in order to 
maintain a normal platelet count under steady-state conditions (41, 42).  This 
tremendous baseline level of production has the potential to markedly increase (by 
≥ 20-fold) in response to contextual cues, including humoral factors resulting from 
malignancies.  Megakaryopoiesis is a highly complex process and is conserved 
across mammalian species.  Nearly one billion megakaryocytes turn over in the 
bone marrow every day (43).  Common myeloid progenitor cells give rise to 
megakaryocyte/erythroid progenitor cells which beget a cellular continuum of 
lineage-committed megakaryocyte progenitor cells with distinct phenotypic 
differences and cytokine requirements.  The most primitive progenitor cell 
committed to megakaryocyte differentiation, the burst-forming megakaryocyte (BFU-
MK), generates colony-forming megakaryocytes (CFU-MK) capable of producing 
several megakaryoblasts.  Megakaryoblasts characteristically have a high 
nuclear/cytoplasmic ratio, round compact nucleus, and basophilic cytoplasm.  While 
megakaryoblasts morphologically resemble lymphocytes, they are readily 
distinguished by their emergent expression of platelet glycoproteins such as β3 
integrin CD61 (GPIIIa) (Figure 1) (44).   
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Figure 1.  Markers of megakaryocyte differentiation and factors influencing 
discrete stages of megakaryocyte maturation.  Changes in cell surface markers 
with megakaryocyte differentiation appear above the purple arrows.  Known 
humoral and signaling factors regulating this process appear under the black arrows 
and purple bar, respectively.  Abbreviations:  glycoprotein (GP), von Willibrand 
Factor (vWF), platelet factor 4 (PF4), thrombospondin (TSP), thrombopoietin (TPO), 
stem cell factor (SCF), c-MPL (TPO receptor).   
 
      As maturation progresses, the megakaryocyte cytoplasm becomes highly 
specialized with the elaboration of a complex system of membranes, called the 
demarcation membrane system, and the aforementioned discrete types of secretory 
granules: alpha granules, dense granules, and lysosomes.  Proteins packaged into 
alpha granules can either be synthesized (eg. platelet factor 4 and von Willibrand 
Factor) or endocytosed (eg. fibrin and growth factors) (45).  Battinelli and 
colleagues postulate that the megakaryocyte uses some type of counting 
 10 
 
mechanism to ensure that each platelet is correctly allocated alpha granules, dense 
granules, and essential organelles (46).    
      Once synthesis of platelet proteins has commenced, the promegakaryoblast 
begins to increase its ploidy by DNA replication without concomitant cell division by 
a unique biological event termed endomitosis (47).  The process of megakaryocyte 
maturation terminates in massive rearrangement of the megakaryocyte cytoskeleton 
into multiple long and branching cytoplasmic extensions known as proplatelets.  The 
demarcation membrane system ultimately serves as the reservoir for proplatelet 
membranes (48).  Beta-1 tubulin largely comprises the internal scaffolding of the 
proplatelet and which forms the “highway” on which cargo from mitochondria and 
granules traffic to the end termini, dispersing into approximately 100-200 platelets 
per terminus.  Proplatelet formation represents a suicidal process for the 
megakaryocyte since it entirely consumes the cytoplasm, leaving behind an 
isolated, apoptotic nucleus (49).   
      Numerous cytokines, such as thrombopoietin (leukemia virus oncogene ligand, 
TPO) and various interleukins, have been implicated in megakaryopoiesis and 
platelet production, many having additive or synergistic effects at various stages in 
the process.  While the cytokines listed in Table 3 are predominantly thought to 
have  a stimulatory effect on megakaryo- and thrombopoiesis, there is some 
evidence that transforming growth factor β1, platelet factor-4, and IL-4 may have 
inhibitory functions (46). 
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   Table 3.  Megakaryo- 
   & thrombopoietic  
   cytokines 
Thrombopoietin 
IL-1α 
IL-3 
IL-4 
IL-6 
IL-11 
Stem Cell Factor 
GM-CSF 
G-CSF 
FLT3 Ligand 
 
      Thrombopoietin is a heavily glycosylated, 332-amino-acid protein and is the key 
humoral factor that drives thrombopoiesis.  It is estimated that TPO stimulates the 
growth of 75% of all CFU-MK (50).  Genetic elimination of TPO or the TPO receptor, 
c-Mpl, in mice reduces platelet counts by approximately 85% of normal (51).  The 
liver is the dominant source of TPO production.  Reciprocal liver transplant 
experiments between normal and TPO-null mice demonstrated that the liver 
synthesizes at least half of all TPO (52).  Under normal physiological conditions, 
blood and marrow levels of TPO are inversely proportional to platelet and 
megakaryocyte numbers.  Since the liver produces TPO at a constitutive rate, TPO 
levels are largely determined by receptor-mediated uptake and degradation by high 
affinity c-Mpl receptors on platelets and megakaryocytes.  Thus, properly regulated 
expression of c-Mpl is critical for controlling thrombopoiesis.  Multiple active and 
inactive splice forms of the c-Mpl receptor exist.  Alternative gene splicing can result 
in the production of truncated receptor proteins inapt for cell surface expression, 
thus resulting in a functional down-regulation of c-Mpl receptors (53).  Substitution 
of a truncated c-Mpl promoter has been shown to result in diminished platelet c-Mpl 
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expression and thrombocytosis (54).  Additionally, platelet c-Mpl receptor 
expression is decreased in patients with essential thrombocythemia, providing 
further evidence that impaired platelet c-Mpl protein expression likely contributes to 
elevated platelet counts (55).  The 8th ATG codon in the 5’ untranslated region of 
TPO mRNA serves as the initiation codon for TPO translation and is embedded in a 
short open reading frame initiated by the 7th ATG.  This juxtaposition of start codons 
results in inefficient TPO translation.  Interestingly, numerous mutations that greatly 
improve the efficiency of TPO translation have been identified in this region and 
linked to familial thrombocytosis (56).    
      There is also evidence to suggest that cytokine-independent mechanisms of 
megakaryopoiesis exist involving chemokine-driven cell interactions mediated by 
fibroblast growth factor (FGF)-4 and stromal-derived factor (SDF)-1 chemokine.  
Recent studies reveal that FGF-4 and SDF-1 guide megakaryocyte progenitors to 
the marrow microvascular niche and that this ligand pair can restore normal platelet 
counts in TPO- and c-Mpl-deficient mice as well as following myelosuppressive 
insults (57).   
      Two transcription factors, GATA-1 and nuclear factor erythroid-2 (NF-E2) are 
also absolutely necessary for terminal megakaryocyte differentiation and release of 
blood platelets (49).  GATA-1 directs platelet-specific gene transcription and is a 
prominent regulator of megakaryocyte endomitosis (31).  NF-E2 regulates the 
expression of many genes important for thrombopoiesis.  Recently, McCormack and 
colleagues demonstrated that the basic helix-loop-helix (bHLH) transcription factor 
SCL acts upstream of NF-E2 to control megakaryocyte differentiation and platelet 
release in instances of thrombopoietic stress, such as following chemotherapy (58).      
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      Any number of aberrations in this intricate process of megakaryo- and/or 
thrombopoiesis could give rise to paraneoplastic thrombocytosis.  While there have 
been some studies examining the link between perturbations in the regulation of 
megakaryo- and/or thrombopoiesis and thrombocytopenia, there has not been a 
concerted effort to identify the determinants of thrombocytosis associated with 
malignancy.  Furthermore, while the supporting function of platelets in metastasis 
has been demonstrated in a variety of experimental models, the contribution of 
platelets to tumor growth and angiogenesis is less well known.  It is also unclear 
when platelet numbers begin to rise during the course of malignant progression and 
if extravascular contact between platelets and tumor cells occurs.  Thus, in order to 
further define the clinical implications, biological role, and underlying mechanism of 
paraneoplastic thrombocytosis in ovarian carcinoma, we undertook the current 
investigation. 
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Hypotheses and Specific Aims 
The overall hypotheses of this project are:   
1)  Thrombocytosis develops in a substantial proportion of patients with advanced 
epithelial ovarian cancer and compromises disease specific survival. 
 
2)  Platelets promote ovarian cancer growth and angiogenesis by increasing tumor 
cell proliferation and migration, supporting microvessel pericyte coverage, and 
sustaining tumor and endothelial cell survival. 
 
3) Increased megakaryo- and thrombopoiesis in response to humoral factors 
resulting from ovarian cancer accounts for paraneoplastic thrombocytosis.   
 
These individual hypotheses can be synthesized into one unified hypothesis.  
Figure 2 illustrates the conceptual framework of the central hypothesis that tumor 
cells, constituents of the tumor microenvironment such as tumor-associated 
endothelial cells, and tumor-bearing host tissues produce megakaryopoietic and 
thombopoietic cytokines, which stimulate megakaryopoiesis and the enumeration of 
platelets, which in turn promote tumor growth and angiogenesis, creating a 
continuous feed-forward loop.  The following specific aims will test this hypothesis. 
 
Specific Aim 1:  Ascertain the prevalence and clinical implications of thrombocytosis 
in human epithelial ovarian cancer. 
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Specific Aim 2:  Examine the biological effects of platelets on ovarian cancer cell 
proliferation and migration, microvessel pericyte coverage, and tumor and 
endothelial cell survival using in vitro and in vivo assays. 
 
Specific Aim 3:  Characterize an underlying mechanism of paraneoplastic 
thrombocytosis in ovarian cancer by identifying megakaryo- and thrombopoietic 
cytokines associated with thrombocytosis in both ovarian cancer patients and 
mouse models of ovarian cancer and by subsequently determining the impact of 
silencing these cytokines on paraneoplastic thrombocytosis in vivo.     
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Figure 2.  Central hypothesis.  The central hypothesis of the present study is that 
tumor cells, constituents of the tumor microenvironment such as tumor-associated 
endothelial cells, and the tumor-bearing host tissues such as the liver parenchyma 
produce megakaryopoietic and thombopoietic cytokines, which stimulate 
megakaryopoiesis and the enumeration of platelets, which in turn promote tumor 
growth and angiogenesis, creating a continuous feed-forward loop.     
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Methods 
Patient clinicopathologic data analysis 
      Following Institutional Review Board approval, clinicopathologic data were 
collected on 619 women with primary epithelial ovarian, primary peritoneal, or 
fallopian tube carcinoma treated at one of 4 U.S. centers including University of 
Texas M.D. Anderson Cancer Center (MDACC) (n=150), University of Virginia 
(n=115), University of Iowa (n=131), and University of Maryland (n=223) between 
1995 and 2007.  Patients with prior histories of cancer, myeloproliferative disorders, 
acute inflammatory diseases or splenectomies were excluded.  All patients 
underwent initial surgical cytoreduction by a gynecological oncologist followed by 6-
8 cycles of taxane/platinum based chemotherapy.  A gynecological pathologist 
reviewed all specimens.  Staging was performed according to the International 
Federation of Gynecology and Obstetrics surgical staging system.  
Clinicopathologic data collected on all patients included age, stage, grade, 
histology, extent of surgical cytoreduction, progression-free interval, disease status, 
and overall survival.  Optimal cytoreduction was defined as residual disease less 
than 1 cm.  Platelet and leukocyte counts as well as hemoglobin (Hgb) and CA-125 
at the time of initial diagnosis were also recorded for all patients.  Thrombocytosis 
was defined as a platelet count greater than 450,000/µL according to the NHLBI 
(59).  The incidence and timing of vascular thromboembolic (VTE) events were 
documented for patients receiving therapy at the Universities of Virginia and Iowa 
(n=246).  The Fisher’s exact test was used to test the associations between platelet 
count at the time of initial diagnosis and clinicopathologic variables with SAS (SAS 
Inc., Cary, NC).  Kaplan-Meier survival curves were generated and compared using 
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a 2-sided log-rank statistic.  Patients who were alive at the time of last follow-up 
were censored.  The Cox proportional hazards model was used for multivariate 
analysis.  A pre-specified subset analysis was preformed in the patients for whom 
VTE events were known to determine the prognostic significance of VTE in patients 
with and without thrombocytosis.  A p value < 0.05 was considered statistically 
significant. 
Cell lines and culture conditions 
      The derivation and source of the human epithelial ovarian cancer cell lines 
A2780ip2, HeyA8, SKOV3ip1, OVCA433, ES2, and 2774 have been described 
previously (60-64).  A2780ip2, HeyA8, SKOV3ip1, and ES2 cells were maintained 
and propagated in RPMI-1640 medium supplemented with 15% fetal bovine serum 
(FBS) and 0.1% gentamicin sulfate (Mediatech Inc. Manassas, VA).  OVCA433 
cells were maintained in MEM supplemented with 10% FBS, 1x L-glutamine 
(200mM stock), 1x MEM vitamins (Invitrogen, Carlsbad, CA), 1x non-essential 
amino acids (NEAA, Mediatech Inc. Manassas, VA), and 0.1% gentamicin sulfate.  
2774 cells were maintained in MEM supplemented with 5% FBS, 1x L-glutamine, 1x 
sodium pyruvate (100mM stock, Invitrogen, Carlsbad, CA), 1x NEAA, and 0.1% 
gentamicin sulfate.  HeyA8-MDR and SKOV3-TR are taxane-resistant variants of 
HeyA8 and SKOV3ip1, respectively (gift from Dr. Isaiah J. Fidler, MDACC, Houston, 
TX).  The phenotype of these cell lines is maintained by adding 300 ng/mL (HeyA8-
MDR) and 100 ng/mL (SKOV3-TR) of paclitaxel to complete media.  ID8 and IG10 
represent cell lines derived from spontaneous malignant transformation of C57BL/6 
mouse ovarian surface epithelium (MOSE) cells in vitro (65, 66).  In this instance, 
we used a more tumorigenic variant VEGF-mutated ID8 strain (ID8VEGF164) 
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generated by transfection with a retroviral vector containing VEGF-164 (gift from Dr. 
George Coukos, University of Pennsylvania Medical Center, Philadelphia, PA) (67).  
For this investigation, we also used the more tumorigenic IG10ip1 line which was 
developed by passaging tumors grown in the mouse intraperitoneal cavity following 
injection of parental IG10 cells (gift from Dr. Isaiah J. Fidler, MDACC, Houston, TX).  
ID8VEGF164 and IG10ip1 cells were maintained in DMEM-F12 supplemented with 5% 
FBS, 1x insulin-transferrin-sodium selenite supplement, (Roche Diagnostics, 
Mannheim, Germany), and 0.1% gentamicin sulfate.  The GILM2 metastatic human 
breast cancer cell line was established from lung metastases of GI101A cells in 
nude mice and has been previously characterized (gift from Dr. Janet Price, 
MDACC, Houston, TX) (68).  GILM2 cells were maintained in DMEM-F12 
supplemented with 10% FBS, 1x L-glutamine, 5% v/v insulin-transferrin-sodium 
selenite supplement, and 0.1% gentamicin sulfate.  The Ishikawa human 
endometrial cancer cell line was maintained in MEM supplemented with 10% FBS 
and 0.1% gentamicin sulfate (gift from Dr. Russell Broaddus, MDACC, Houston, TX) 
(69).  NOD/SCID mice bearing heterotopic pancreatic tumors derived from patient 
samples were a gift from Dr. Gary Gallick (MDACC, Houston, TX).  The derivation 
and characterization of murine ovarian endothelial cells (MOECs, gift of Dr. Robert 
Langley, MDACC, Houston, TX) and of pericyte-like murine vascular smooth muscle 
cells (C3H/10T1/2, ATCC) have been described previously (70, 71).  MOECs were 
maintained in DMEM supplemented with 5% FBS and 0.1% gentamicin sulfate.  
Pericyte 10T1/2 cells were maintained in BME supplemented with 10% FBS, 
recombinant bFGF (10 ng/mL), and 0.1% gentamicin sulfate.   All experiments were 
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performed using cells grown to 60-80% confluence.  All cell lines were routinely 
genotyped and tested to confirm absence of Mycoplasma.   
Determination of platelet counts in mouse models of ovarian, breast, uterine, and 
pancreatic cancer 
      Female athymic nude (NCr-nu) and C57BL/6 mice were purchased from 
Taconic Farms Inc. (Rockville, MD) or Experimental Radiation Oncology (MDACC, 
Houston, TX), respectively.  All experiments were approved and supervised by the 
MDACC Institutional Animal Care and Use Committee.  The development and 
characterization of the orthotopic mouse model of advanced ovarian cancer used in 
this investigation has been previously described by our laboratory (72-74).    Briefly, 
A2780ip2 (1x106), HeyA8 (0.25 x 106), or 2774 (2x106) human ovarian cancer cells 
resuspended in 200 µL of Hank’s balanced salt solution (HBSS, Mediatech Inc. 
Manassas, VA) were injected into the peritoneal cavity of female nude mice.  
A2780ip2 and HeyA8 reliably form macroscopic tumor implants in the adnexa, 
peritoneum, small bowel mesentery, omentum, and porta hepatis (tumor-bearing 
mice, n=9) while 2774 also produces large volume ascites (tumor- and ascites-
bearing mice, n=7).  Immunocompetent in vivo models based on syngeneic mouse 
ovarian epithelial cancer cells physiologically and biologically closely resemble 
human epithelial ovarian cancer.  These models were generated by injecting 
ID8VEGF164 or IG10ip1 (1x106) cells resuspended in 200uL HBSS into the peritoneal 
cavity of female C57BL/6 mice (n=6).  Once tumors and/or ascites were detectable 
on physical exam, whole blood was collected from anesthetized mice by intra-
cardiac stick and processed for complete blood counts (CBCs) by the MDACC 
veterinary laboratory.  Blood was similarly collected and processed for CBCs from 
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healthy female nude and C57BL/6 mice (n=8) for comparison.  Additionally, tumor 
weight and number of intraperitoneal metastases were quantified in the tumor- and 
ascites-bearing orthotopic model.  The orthotopic nude mouse model of human 
metastatic breast cancer used in this investigation was generated by injecting 1x106 
GILM2 cells under direct visualization into the second mammary fat pad though a 
posterior incision.  By 6 weeks all mice had developed ≥ 1 cm tumors and blood 
was collected for CBCs (n=7).  The development and characterization of the 
orthotopic mouse model of uterine cancer used in this investigation has been 
previously described by our laboratory (75).  Briefly, mice were anesthetized and a 
0.5 cm incision was made in the left lower flank to expose the left uterine horn.  The 
distal portion of the horn was brought up to the incision and a single-cell suspension 
of 4x106 Ishikawa cells in 50 µL was injected into the lumen.  By 6 weeks, all mice 
had developed palpable tumors and blood was collected for CBCs (n=6).  
NOD/SCID mice bearing heterotopic human pancreatic cancer xenografts were 
obtained from Dr. Gary Gallick.  Methodology for heterotopic implantation of tumor 
fragments from patient specimens, processing of direct xenograft tumors into single-
cell suspensions, and heterotopic reimplantation of pancreatic cancer cells into 
NOD/SCID mice has been recently published (76).  When xenografts reached 
approximately 1 cm in diameter, blood was collected for CBCs.  All measurements 
are represented as the average ± S.E. of the mean.  Two-tailed Student’s t-test was 
used to compare blood counts between tumor-bearing mice ± ascites and healthy 
controls.  Pearson’s correlation coefficient was used to test associations between 
platelet counts, tumor weight, and number of intraperitoneal metastases in tumor- 
and ascites-bearing mice. 
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Characterization of the onset and longitudinal progression of thrombocytosis in an 
orthotopic mouse model of ovarian cancer               
      For this time course experiment, we utilized a HeyA8-luciferase-transfected cell 
line (HeyA8-Luc) that had been previously established in our laboratory with a 
lentivirus system (77).  On day 1, 50 mice received i.p. injections of HeyA8-Luc cells 
and were subsequently divided into 5 groups (n=10 per week) for weekly 
quantification of tumor burden and platelet counts.  Due to the detection limits of 
physical exam, bioluminescence imaging was used to detect disease in groups 1 
and 2 on days 8 and 15, respectively.  Bioluminescence imaging was conducted on 
a cryogenically cooled IVIS 100 imaging system coupled to a data acquisition 
computer running Living Image software (Xenogen).  Before imaging, animals were 
anesthetized in an acrylic chamber with 1.5% isoflurane/air mixture and injected i.p. 
with 15 mg/mL of D-luciferin firefly potassium salt (Caliper Life Sciences, Hopkinton, 
MA) in PBS at a dose of 150 mg/kg body weight.  A digital gray-scale animal image 
was acquired followed by acquisition and overlay of a pseudocolor image 
representing the spatial distribution of detected photon emerging from active 
luciferase within the animal.  In our experience, the lower limit of detection for 
bioluminescence imaging using the IVIS system is 0.5-1x104 and 0.5-1x106 cells 
injected subcutaneously and i.p., respectively (unpublished data).  The presence of 
macroscopic disease could be reliably detected on physical exam starting on day 
22.  Blood was collected for platelet counts following imaging of groups 1 and 2 on 
days 8 and 15 and prior to sacrificing groups 3, 4, and 5 for necropsy and 
measurement of tumor weight on days 22, 29, and 36, respectively.         
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YFP-labeled platelet isolation, transfusion, and localization in ovarian tumors and 
ascites 
      YFP-labeled platelets were isolated from whole blood obtained from female 
transgenic C57BL/6 mice expressing yellow fluorescent protein (YFP) under the 
control of the PF4 platelet specific promoter (gift from Dr. Francisca Gushiken, 
Thrombosis Research Section in Baylor College of Medicine, Houston TX).  In this 
mouse strain, YFP protein is exclusively present in megakaryocytes and platelets.  
We used standard techniques to collect blood and prepare platelet rich plasma 
(PRP) from these mice (78).  Briefly, 1 mL of whole blood was withdrawn into a 
syringe preloaded with 1.9 v/v acid-citrate dextrose solution (ACD, 75 mM trisodium 
citrate, 124 mM dextrose, and 38 mM citric acid) from anesthetized mice by 
intracardiac stick.  PRP was separated from red blood cells and leukocytes by room 
temperature centrifugation of citrated whole blood at 540 rpm for 10 minutes.  This 
yielded approximately 500 µL of PRP containing 300x106 YFP-labeled platelets, 
which was then transfused into ID8VEGF164 tumor-bearing mice by tail vein injection.  
After 1 hour had elapsed, recipient mice were anesthetized and perfused with 4% 
paraformaldehyde through the ascending aorta for 2 minutes for intravital fixation of 
tumor tissue.  Intravital fixation was necessary in order to circumvent spillage of 
YFP-labeled platelets into the tumor bed that can occur as an artifact of dissecting 
fresh tissue.  Following intravital fixation, tumors were resected, immersed in 30% 
sucrose overnight, and then embedded in OCT.  Immunofluorescent (IF) staining of 
frozen sections for CD31 antigen to label the tumor vasculature was then 
performed.  Sections were washed in PBS, blocked with 4% fish gel for 20 minutes, 
and probed with rat anti-mouse CD31 diluted in protein block (1:800, BD 
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Pharmingen, San Diego, CA) at 4ºC overnight.  Sections were again washed in 
PBS, blocked with 4% fish gel for 10 minutes, and incubated with goat anti-rat Alexa 
594 diluted in protein block for 1 hour at room temperature (1:800, Invitrogen, 
Eugene, OR).  After extensive washing in PBS, nuclei were counterstained with 
Hoechst (1:10,000 diluted in PBS, Invitrogen, Carlsbad, CA) for 10 minutes.  
Images were captured at x200 magnification.  Whole mounts of ascites were 
immediately prepared and examined by fluorescent and confocal microscopy upon 
removal of ascites by paracentesis 1 hour following YFP-platelet transfusion, but 
prior to intravital fixation.  Microscopy was performed using a band pass emission 
filter for peak wavelength of 519 nm given that the emission peak of YFP is 527 nm.             
Evaluation of the effect of platelet depletion on tumor growth and biology 
      To deplete platelets in mice, we used an antibody preparation of purified rat 
monoclonal antibodies directed against mouse glycoprotein (GP) Ibα (CD42b, 
Emfret Analytics, Eibelstadt, Germany).  Originally developed to study the 
pathogenic effects of anti-platelet antibodies in autoimmune thrombocytopenic 
purpura, this antibody causes irreversible Fc-independent platelet depletion in mice 
within 60 minutes of administration without inducing platelet activation.  To identify 
the optimal dose and treatment schedule of antibody for subsequent therapy 
experiments, we first determined the dose-time kinetics of antibody mediated 
platelet depletion.  Platelets were quantified on days 2 and 7 following a single tail 
vein injection of 0.5 to 4 µg/g body weight of antibody.  Given that the 0.5 µg/g dose 
of antibody decreased platelet counts by 50% with return to baseline on day 4, we 
administered this dose of antibody every 4 days for in vivo studies (Figure 3).   
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Figure 3.  Dose-time kinetics of platelet depletion in mice using anti-platelet 
antibody (APA, anti-mouse glycoprotein 1bα antibody).       
 
      Prior to initiating in vivo therapy experiments, we also used flow cytometric 
analysis to confirm the specificity of this antibody for platelets in order to exclude the 
possibility that antibody recognition of cells other than platelets such as pericytes, 
tumor and endothelial cells might account for observed anti-tumor and/or anti-
angiogenic effects.  Nude mouse platelets, A2780ip2 ovarian cancer cells, MOECs, 
and 10T1/2 cells were incubated with the GP Ibα antibody for 1 hour.  Antibody 
binding was assessed by flow cytometry following a 1 hour incubation with an anti-
rat secondary antibody conjugated to APC.  Only mouse platelets labeled positively.  
In all other instances, the APC signal did not differ from the negative control (APC 
secondary antibody alone) (Figure 4).   
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Figure 4.  Confirmation of the specificity of anti-platelet antibody (APA) for 
mouse platelets.  Mouse platelets, A2780ip2 human ovarian cancer cells, murine 
ovarian endothelial cells (MOEC), and pericyte-like murine vascular smooth muscle 
cells (T101/2) were incubated with APA for 1 hour.  Binding of secondary antibody 
conjugated to APC was detected using flow cytometry.   
   
      After characterizing the activity and specificity of the antibody, we evaluated the 
effect of platelet depletion on tumor growth in an orthotopic mouse model of ovarian 
cancer.  Treatment was initiated 8 days after the introduction of A2780ip2 ovarian 
cancer cells i.p.  Mice were treated with either 0.5 µg/g anti-GP1bα antibody or 
control IgG by tail vein injection every 4 days until they became moribund 
(n=10/group).  Tumor weight was recorded at the time of necropsy and tumor tissue 
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was harvested for histopatholoigcal analysis.  Proliferation index and microvessel 
density were evaluated in tumor sections with immunohistochemical staining for 
Ki67 and CD31 antigens, respectively.  Frozen sections were fixed in acetone + 
chloroform 1:1 for 5 minutes between two 5 minute incubations in cold acetone 
alone.  Endogenous peroxidases and non-specific epitopes were blocked with 3% 
H2O2 in PBS and 5% normal horse serum + 1% normal goat serum in PBS, 
respectively.  Sections were then incubated with primary antibody directed against 
either Ki-67 (1:200, Neomarker, Fremont, CA) or CD31 (1:800, PharMingen, San 
Diego, CA) at 4°C overnight.  After washing with PBS, the appropriate HRP-
conjugated secondary antibody in blocking solution was added for 1 hour at room 
temperature.  Slides were developed with 3, 3’-diaminobenzidine (DAB) chromogen 
(Invitrogen, Carlsbad, CA) and counterstained with Gil No.3 hematoxylin (Sigma-
Aldrich, St. Louis, MO).  Proliferative index was calculated by dividing the number of 
Ki67 positive nuclei (brown) by the total number of cells for each of 5 randomly 
selected x200 high power fields per tumor specimen for each treatment group.  
MVD was calculated by viewing 5 representative x100 fields per slide in each 
treatment group and counting the number of microvessels per field.  A microvessel 
was defined as an open lumen with at least one CD31-positive cell immediately 
adjacent to it (79, 80).   
      Dual immunofluorescent staining for CD31 and desmin was used to assess 
pericyte coverage.  Fixed frozen sections were first probed with CD31 antibody as 
described above.  After washing with PBS, the sections were incubated with Alexa 
594-conjugated anti-rat antibody (1:1000, Invitrogen, Eugene, OR) for 1 hour at 
room temperature.  After extensive washing with PBS, sections were next probed 
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with anti-desmin antibody (1:400, DakoCytomation, Denmark) for 2 hours, followed 
by washing with PBS and incubation with Alexa 488-conjugated anti-rabbit antibody 
(1:1000, Invitrogen) for 1 hour at room temperature.  Nuclei were counterstained 
with Hoechst.  To quantify pericyte coverage, we calculated the endothelial cell (red 
staining) to pericyte ratio (green staining) for 5 random high power fields at x200 
magnification by dividing the number of pericytes by the number of endothelial cells.   
      Tumor and endothelial cell apoptosis was examined with dual 
immunofluorescent staining for CD31 and terminal deoxynucleotidyl transferase 
dUTP nick end labeling (TUNEL).  Fixed frozen sections were first probed with 
CD31 antibody, as described above.  Slides were washed in PBS, fixed again in 4% 
paraformaldehyde in PBS, washed twice in PBS, and incubated with 0.2% Triton X-
100 in PBS for 15 minutes. After two more washes in PBS, slides were incubated 
for 10 minutes with the equilibration buffer in the TUNEL detection kit (Promega, 
Madison, WI). Equilibration buffer was removed, and reaction buffer (consisting of 
equilibration buffer in the kit, fluorescein-12-dUTP [where dUTP is deoxyribouridine 
triphosphate], and terminal deoxynucleotidyltransferase) was then added. After 1-
hour incubation at 37°C in the dark, the reaction was stopped by addition of the 
provided 2x standard saline-buffered citrate (8.77 g of NaCl, 4.41 g of sodium 
citrate, and 400 mL of deionized water) for 15 minutes.  Excess dUTP was removed 
by washing, and nuclei were stained with Hoechst (Molecular Probes, in PBS; 1.0 
µg/mL) for 10 minutes.  The total number of apoptotic tumor cells (green nuclei 
alone) and CD31-positive cells (red cells plus green nuclei) were counted.  Controls 
included exposure to only secondary antibodies, exposure to reaction buffer that did 
not contain terminal deoxynucleotidyltransferase, and exposure to DNase to 
 29 
 
fragment the DNA (positive control).  Apoptotic cells were counted in 5 random 
microscopic fields from each tumor at x200 magnification.  Microscopy was 
performed with a Zeiss AxioPlan 2 microscope, Hamamatsu ORCA-ER digital 
camera, and ImagePro software.  All measurements are represented as the 
average ± S.E. of the mean.  Two-tailed Student’s t test was used to make 
comparisons between the two treatment groups.  A p-value of < 0.05 was 
considered statistically significant.     
In vitro assays evaluating the effect of platelets on ovarian cancer cell migration, 
proliferation, and survival 
      Citrated plasma is not an ideal medium for evaluating platelet function due to 
factors such as plasma protein content, calcium chelation, and platelet agglutination 
by the action of thrombin.  Therefore, we used plasma-free platelets prepared with 
sterile technique for in vitro assays.  Whole blood withdrawn into a syringe 
preloaded with 1.9 v/v acid-citrate dextrose solution from anesthetized mice by 
intracardiac stick was gently mixed with 1:1 v/v tyrodes buffer (140 mM NaCl, 2.7 
mM KCl, 12 mM NaHCO3, 6.45 mM NaH2PO4, 5.5 mM glucose in diH20) lacking 
Mg2+ and Ca2+.  PRP was separated from red blood cells and leukocytes by room 
temperature centrifugation of blood at 540 rpm for 10 minutes.  A plasma-free 
platelet suspension was then prepared by passing PRP through a gel filtration 
column of Sepharose 2B (Sigma Aldrich, St Louis, MO).  Specifically, a siliconized 
glass column containing a 10 µm nylon net filter was assembled (Millipore, Billerica, 
MA).  Sepharose 2B beads were equilibrated by washing in acetone (3-4 vol.), 
followed by 0.9% NaCl (5-6 vol.), and buffer 1 (5-6 vol. 134 mM NaCl, 12 mM 
NaHCO3, 2.9 mM KCl, 0.34 mM Na2HPO4, 1 mM MgCl2, 10 mM Hepes, 5 mM 
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glucose, 0.3g/100 mL BSA, pH 7.4).  The beads were loaded onto the column and 
washed again with buffer 1 (2-3 vol.).  PRP was then applied to the column and 
allowed to completely enter the gel before adding additional buffer 1 (2-3 vol.).  The 
eluate was discarded until it began to change from clear to opaque, signifying the 
presence of platelets.  The opaque platelet fraction was collected in a fresh 
polyethylene tube until the eluate again began to clear.  Platelets were counted with 
a hemocytometer by phase microscopy at x400 magnification.  Platelets present in 
all 25 of the small squares in the center of each chamber of the hemocytometer 
were counted and the mean value gives a platelet count x103/uL.   
      Migration assays were performed to determine if ovarian cancer cells have a 
chemotactic response to platelets.  A modified Boyden chamber with upper and 
lower wells separated by a 0.1% gelatin coated cell-permeable membrane was 
used for these assays.  Platelets (100x106) or equal volumes of buffer 1 were added 
to serum free cell culture media in the bottom wells.  Since platelets were eluted in 
buffer 1, an equal volume of buffer 1 was used as the vehicle control.  A2780ip2, 
HeyA8, or 2774 ovarian cancer cells suspended in serum free cell culture media 
were added to the top wells (100,000 cells per well).  Chambers were incubated for 
6 hours at 37ºC.  At completion, cells in bottom chambers were removed with 0.1% 
EDTA, loaded onto a 3.0 micron polycarbonate filter (Osmonics, Livermore, CA) 
using an S&S Minifold I Dot-Blot System (Schleicher & Schuell, Keene, NH), fixed, 
stained, and counted by light microscopy.  Cells from 5 random fields (final 
magnification x100) were counted.   
      The effect of platelets on ovarian cancer cell proliferation and survival was 
evaluated in A2780ip2, HeyA8, SKOV3ip1, OVCA433, ES2, and 2774 cell lines.  
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Plasma-free platelets were prepared as described above.  For proliferation assays, 
cells were plated in 6-well plates (50,000 per well) and serum starved overnight.  
The following day, 20x106 platelets suspended buffer 1 were directly added to each 
well for a final concentration of 10x106 platelets per mL serum free media.  Cells 
treated with an equal volume of buffer 1 served as controls.  After cells were co-
cultured with platelets for 24 hours, the percentage of proliferating cells was 
determined using the Click-iT EdU flow cytometry assay kit (Invitrogen).  Cells were 
incubated with 10 µM 5-ethynyl-2’-deoxyuridine (EdU, modified BrdU nucleoside 
analog) for 1 hour, harvested, and washed with 1% BSA/PBS.  Following overnight 
fixation with 4% paraformaldehyde in PBS at 4ºC, cells were washed in 1% 
BSA/PBS and permeabilized with 1X saponin-based permeabilization reagent for 20 
minutes at room temperature.  S-phase cells were then detected by incubating cells 
with Click-iT detection cocktail containing 1x Click-iT reaction buffer, CuSO4, Alexa 
Fluor 488 azide dye, and reaction buffer additive for 30 minutes at room 
temperature prior to flow cytometry. 
      For cytotoxicity assays, cells were plated in 10 cm plates (300,000 per plate).  
The following day 100x106 platelets were directly added to each well for a final 
concentration of 10x106 platelets per mL of serum free media ± 0.5 nM docetaxel.  
Cells treated with an equal volume of buffer served as controls.  After co-culturing 
cells with platelets ± docetaxel for 72 hours, cell viability was assessed with 
propidium iodide (PI) by flow cytometry.  Cells were harvested, washed in PBS, and 
fixed with 20% EtOH in PBS at 4ºC overnight.  Prior to flow cytometric analysis, 
cells were washed in PBS and incubated with 500 µL PI + RNAse (50 µg/mL in PBS 
+ 20 µg/mL RNAse) for 10 minutes.   
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      Western blot analysis was used to evaluate PDGFRα expression in the ovarian 
cancer cell lines subjected to proliferation and cytotoxicity experiments as well as in 
the taxane-resistant cell lines HeyA8-MDR and SKOV3-TR.  Cell lysate was 
prepared from ovarian cancer cells in log growth phase at 70% confluency.  Cells 
were washed with PBS, lifted by scraping, and lysed with modified 
radioimmunoprecipitation assay (RIPA) lysis buffer with 1x protease inhibitor 
(Roche, Mannheim, Germany) and 1 mM sodium orthovanadate for 20 minutes on 
ice.  Cell lysate was centrifuged at 13,000 rpm for 20 min at 4ºC. Protein 
concentration was determined by a bicinchoninic acid protein assay reagent kit.  
Forty micrograms of protein from whole-cell lysate was fractionated by 6% SDS-
PAGE, transferred to nitrocellulose, blocked with 5% nonfat milk for 1 hour at room 
temperature and probed with primary antibody (1:500, Millipore, Temecula, CA) at 
4ºC overnight. Blots were then incubated with horseradish peroxidase conjugated 
anti-rabbit secondary antibody (1:3000, The Jackson Laboratory, Bar Harbor, ME).  
Blots were developed with use of an enhanced chemiluminescence detection kit 
(ECL, Amersham Pharmacia Biotech, Piscataway, NJ). To ensure equal protein 
loading, a monoclonal vinculin antibody (1:1000, Sigma-Aldrich, St. Louis, MO) was 
used. 
      To determine whether taxane resistance conferred by platelets could be 
mediated through PDGFRα, SKOV3ip1 cells were pretreated with the fully 
humanized anti-PDGFRα antibody, IMC-3G3 (100 µg/mL in PBS, Imclone, New 
York, New York), for 2 hours.  Treatment was then continued with either IMC-3G3, 
0.5 nM docetaxel, or the combination ± platelets (10x106/mL) for 72 hours.  Flow 
cytometric assay of PI staining was used to quantify cell death as described above.      
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All measurements are reported as mean change relative to vehicle control ± SEM of 
triplicate experiments.  Two-tailed Student’s t test was used to make comparisons 
between groups.  A p-value of < 0.05 was considered statistically significant.  
Megakaryocyte quantification 
      The lung, liver, spleen, and femur/tibia were harvested from healthy nude mice 
and mice with A2780ip2, HeyA8, and 2774 orthotopic human ovarian cancers (n = 5 
per group), fixed in 10% buffered formalin overnight, paraffin embedded, and 
sectioned.  Prior to paraffin embedding, bones were decalcified in 10% EDTA (pH 
7.4) for 10 days.  Tissue sections were hemotoxylin-eosin stained and examined by 
light microscopy.  Mature megakaryocytes were readily identified by their large size 
(50-100 µm), multilobulated nuclei, and abundant granular, eosinophilic cytoplasm 
(81).  The number of megakaryocytes per 5 randomly selected x200 high power 
fields was recorded.  Pearson’s correlation coefficient was used to test the 
associations between mean platelet counts and mean megakaryocyte counts in the 
spleen and bone marrow across control and tumor-bearing mice ± ascites.         
Detection of thrombopoietin transcript by RT-PCR 
      Total RNA was extracted from A2780ip2 and 2774 cells growing in vitro and 
liver tissue from healthy nude mice and mice with orthotopic HeyA8 tumors using 
guanidinium thiocyanate-phenol-chloroform (TRIzol, Invitrogen) extraction.  Cells 
were washed twice with cold PBS and fresh frozen liver (0.3 grams per sample) was 
pulverized to a fine powder in liquid nitrogen by mortal and pestle before the 
addition of 1 mL of TRIzol.  Samples were transferred to sterile microfuge tubes, 
combined with 200 µL of chloroform, and centrifuged at 12,000 g for 10 minutes at 
4ºC.  The upper aqueous layer was then transferred to a fresh tube and RNA was 
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precipitated by adding 0.5 mL of isopropanol.  RNA was pelleted by centrifugation, 
washed once with 75% ethanol, and dissolved in 25 µL of RNase-free water.  RNA 
was quantified by spectrophotometer and 1 µg transcribed into complementary DNA 
(cDNA) using the Verso cDNA kit (Thermo Fisher Scientific) according to the 
manufacturer’s protocol.  The cDNA was then used for PCR amplification of TPO 
and β-actin according to the following conditions:  94°C for 5 minutes for denaturing, 
followed by 32 cycles of melting at 94°C for 45 seconds and annealing-extending 
with Taq thermostable polymerase (at the Tm specific to the primer set) for 60 
seconds, followed by a final step at 72°C for 10 minutes.  The primers used for PCR 
amplification were human TPO sense (5′-TGTCCTTCACAGCAGACTGA-3′) and 
antisense (5′-GTGTTGGAAGCTCAGGAAGA-3′) Tm 55ºC, murine TPO sense (5′-
CCCAATGCCCTCTTCTTGAG-3′) and antisense (5′-
GAGCAAGGCTTGGAGAAGGA-3′) Tm 66ºC, and β-actin sense (5′-
ATCTGGCACCACACCTTCTACAATGA-3′) and antisense (5′-
CGTCATACTCCTGCTTGCTGATCCAG-3′) Tm 62ºC.  Amplified PCR products 
were analyzed by electrophoresis on 1.5% agarose gel with Tris-borate-EDTA 
buffer and visualized under UV light after staining with ethidium bromide.                           
Detection of thrombopoietin protein expression by immunohistochemical staining 
      Immunohistochemical staining was used to assess TPO expression in 
A2780ip2, HeyA8, and 2774 tumors and in a panel of 10 human serous papillary 
ovarian cancers (5 patients with normal platelet counts and 5 patients with 
thrombocytosis).  Paraffin embedded tumor sections were deparaffinized 
sequentially in xylenes and declining grades of ethanol prior to rehydration.  Antigen 
retrieval was performed by steaming slides at 100ºC for 30 minutes in 0.01M 
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sodium citrate buffer, pH 6.0.  Nonspecific epitopes were blocked with 10% fish 
gelatin in 1x TBS with Tween (TBST).  Sections were incubated with rabbit anti-
human thrombopoietin antibody (1:1000) overnight at 4ºC.  After washing with 
TBST, sections were incubated with 4plus biotinylated anti-rabbit IgG followed by 
4plus streptavidin-HRP (Biocare Medical, Concord, CA) for 20 minutes at room 
temperature.  Slides were developed with DAB chromogen (Invitrogen) and 
counterstained with Gil No.3 hematoxylin (Sigma-Aldrich).   
Multiplex platform for quantification of megakaryo- and thrombopoietic cytokine 
levels in patient plasma samples 
      Quantitative multiplex detection of plasma cytokines in banked plasma collected 
from 150 patients at the time of primary tumor reductive surgery for advanced, high 
grade epithelial ovarian cancer was accomplished using Milliplex™ human 
cytokine/chemokine panels (Millipore) coupled with the Luminex® xMAP® platform.  
Platelet counts obtained at preoperative clinic visits were recorded for each patient.  
Banked plasma was separated from whole blood collected in EDTA blood collection 
tubes by centrifuging for 10 minutes at 1000 g.  We customized human cytokine 
panel I for detection of Flt-3 Ligand, G-CSF, GM-CSF, IL-1α, IL-3, IL-4, and IL-6.  
Human cytokine panel II was customized for TPO and SCF and panel III was 
customized for IL-11.  Immunoassay procedure was executed according to the 
manufacturer’s protocol.  Briefly, microtiter filter plates were prewetted with assay 
buffer on a plate shaker for 10 minutes at room temperature.  Assay buffer was 
removed by vacuum and each standard or positive control was added to the 
appropriate wells.  Assay buffer was used for the 0 pg/mL standard (background).  
After adding assay buffer and serum matrix to the sample wells, 25 µL of each 
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patient sample was added to the appropriate wells in duplicate.  Prior to use in the 
assay, patient plasma samples were thawed on ice, mixed well by vortexing, and 
centrifuged at 1100 rpm for 3 minutes.  Antibody-immobilized beads for detection of 
individual cytokines were mixed by sonication and vortexing.  For cytokine panel I, 
60 µL aliquots of antibody-immobilized beads directed against Flt-3 Ligand, G-CSF, 
GM-CSF, IL-1α, IL-3, IL-4, or IL-6 were combined and brought to a final volume of 3 
mL with bead diluent.  For cytokine panel II, 60 µL aliquots of antibody-immobilized 
beads directed against TPO or SCF were combined and brought to a final volume of 
3 mL with bead diluent.  For cytokine panel III, 60 µL of antibody-immobilized beads 
directed against IL-11 was combined with 2.94 mL of bead diluent.  After adding 25 
µL of mixed beads corresponding to the cytokines included in panels I, II, or III to 
the wells of the appropriate microtiter plates, plates were incubated with agitation on 
a plate shaker for 1 hour at room temperature.  Fluid was completely removed by 
vacuum, leaving the bound immunobeads behind to be incubated with detection 
antibodies followed by streptavidin-phycoerythrin for 30 minutes.  Fluid was 
removed by vacuum, the plates were washed twice, and sheath fluid added to all 
wells.  The plates were run on a Luminex 200™ platform and the Median 
Fluorescent Intensity (MIF) data were analyzed using a 5-parameter logistic curve-
fitting method for calculating cytokine concentrations in patient samples.  To 
determine whether plasma thrombopoietic cytokine levels were associated with 
platelet count, we calculated Spearman’s r for each pairwise association and tested 
for a statistically significant difference from 0.  We used Wilcoxon rank sum test to 
test differences in cytokine levels between patients with normal platelet counts and 
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patients with thrombocytosis.  A p-value < 0.05 was considered statistically 
significant.      
Use of human- and murine-specific ELISAs for quantification of plasma IL-6, GCSF, 
and TPO levels in mouse models of ovarian cancer  
      Whole blood from healthy control mice and mice with A2780ip2, HeyA8, 2774, 
and ID8 tumors (n=4 per group) was collected by intracardiac stick with syringes 
preloaded with 0.1cc of ACD anticoagulant.  Plasma was isolated by centrifugation 
at 1800 rpm for 10 minutes and stored at -80ºC until use.  Plasma IL-6, GCSF, and 
TPO levels were measured using human- and murine-specific Quantikine® ELISAs 
in order to differentiate between orthotopic human ovarian cancers and the murine 
host as the source of cytokine production (R&D Systems, Minneapolis, MN).  The 
assays were performed as recommended by the kit manufacturer.  After 
development of the colorimetric reaction, the absorbance at 450 nm was quantified 
by spectrophotometer and the absorbance readings were converted to pg/ml based 
on standard curves generated with recombinant cytokine in each assay.  
Absorbance readings never exceeded the linear range of the standard curves.  
Differences in cytokine expression from baseline levels in healthy controls were 
tested using Student’s t-test with significance set at p < 0.05.                 
In vivo experiments evaluating the effect of silencing IL-6, G-CSF, and TPO on 
thrombocytosis 
      Human- and murine-specific siRNA oligonucleotides targeted against IL-6, G-
CSF, and TPO mRNA were purchased from Sigma-Aldrich (The Woodlands, TX).  
Three oligonucleotides designed against each target except human G-CSF were 
initially screened for efficacy of gene silencing in vitro.  Human G-CSF siRNA was 
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not included because A2780ip2 and 2774 human ovarian cancer cells were not 
found to express G-CSF.  The siRNA oligonucleotide sequences that we screened 
are listed in Table 4.  The sequence that most effectively blocked the expression of 
each target was selected for gene silencing in vivo and is highlighted in red.    
 
Table 4.  siRNA sequences screened for targeting TPO, IL-6, and G-CSF 
siRNA oligo ID Sense Sequence Anti-sense Sequence 
hTPO sequence 1 5’GACAUUCUGGGAGCAGUGA3’ 5’UCACUGCUCCCAGAAUGUC3’ 
hTPO sequence 2 5’GACAUUUCCUCAGGAACAU3’ 5’AUGUUCCUGAGGAAAUGUC3’ 
hTPO sequence 3 5’GAGACAACUGGACAAGAUU3’ 5’AAUCUUGUCCAGUUGUCUC3’ 
mTPO sequence 1 5’GAGAUAUACUGCUCUUGAU3’ 5’AUCAAGAGCAGUAUAUCUC3’ 
mTPO sequence 2 5’CACUAAACAAGUUCCCAAA3’ 5’UUUGGGAACUUGUUUAGUG3’ 
mTPO sequence 3 5’GAAUUAACAGGCUAUCACU3’ 5’AGUGAUAGCCUGUUAAUUC3’ 
hIL-6 sequence 1 5’CUUCCAAUCUGGAUUCAAU3’ 5’AUUGAAUCCAGAUUGGAAG3’ 
hIL-6 sequence 2 5’CUCACCUCUUCAGAACGAA3’ 5’UUCGUUCUGAAGAGGUGAG3’ 
hIL-6 sequence 3 5’CAUGUAACAAGAGUAACAU3’ 5’AUGUUACUCUUGUUACAUG3’ 
mIL-6 sequence 1 5’CGAUGAUGCACUUGCAGAA3’ 5’UUCUGCAAGUGCAUCAUCG3’ 
mIL-6 sequence 2 5’GCAUAUCAGUUUGUGGACA3’ 5’UGUCCACAAACUGAUAUGC3’ 
mIL-6 sequence 3 5’CAGAAACUCUAAUUCAUAU3’ 5’AUAUGAAUUAGAGUUUCUG3’ 
mGCSF sequence 1 5’CCUUUCCAGAUAGUUUAUU3’ 5’AAUAAACUAUCUGGAAAGG3’ 
mGCSF sequence 2 5’GGAAGGAGAUGGGUAAAUA3’ 5’UAUUUACCCAUCUCCUUCC3’ 
mGCSF sequence 3 5’GCUUAAGUCCCUGGAGCAA3’ 5’UUGCUCCAGGGACUUAAGC3’ 
 
      For in vitro screening, siRNA (5 µg) was incubated with 30 µL Lipofectamine 
2000 reagent (Invitrogen) for 20 minutes at room temperature and added to cells 
grown to 50% confluence in 10 cm culture plates.  The transfection was exchanged 
with serum containing media after 6 hours, and cells harvested at 24, 36, 48, and 72 
hour time points following transfection for assessment of target knockdown by RT-
PCR, western blot, or ELISA.  A nontargeting siRNA sequence, shown by BLAST 
search to not share sequence homology with any known human or murine mRNA 
(target sequence 5'-AAUUCUCCGAACGUGUCACGU-3') was used as control.  RT-
PCR was used to screen candidate human (hTPO) and murine (mTPO) TPO siRNA 
sequences for efficacy of TPO gene silencing.  MOEC and 2774 cells were 
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harvested 24 and 48 hours following transfection with murine or human TPO siRNA 
oligonucleotides, respectively.  RNA extraction, cDNA synthesis, and PCR 
amplification of human TPO, murine TPO, and β-actin were performed as previously 
described.  Amplified PCR products were analyzed by electrophoresis on 1.5% 
agarose gel with Tris-borate-EDTA buffer and visualized under UV light after 
staining with ethidium bromide.  Near complete silencing of human and murine TPO 
expression was achieved by 48 hours using siRNA sequence 2 in each case. 
(Figure 5, green boxes).   
 
 
Figure 5.  Selection of effective siRNA sequences for targeting thombopoietin.  
RT-PCR was used to screen three candidate human thrombopoietin (hTPO) (a) and 
murine thrombopoietin (mTPO) (b) siRNA sequences (seq 1-3).  A nontargeting 
siRNA sequence was used as control (csi).      
 
      Human TPO knockdown with siRNA sequence 2 was then validated at the 
protein level using western blot analysis.  Cells were transfected with human TPO 
siRNA sequence 2, harvested at 24, 48, and 72 hour time points, and lysed with 
modified radioimmunoprecipitation assay (RIPA) lysis buffer with 1x protease 
inhibitor (Roche, Mannheim, Germany) and 1 mM sodium orthovanadate for 20 
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minutes on ice.  Cell lysate was centrifuged at 13,000 rpm for 20 min at 4ºC.  
Protein concentration was determined by a bicinchoninic acid protein assay reagent 
kit.  Forty micrograms of protein from whole-cell lysate was fractionated by 12% 
SDS-PAGE, transferred to nitrocellulose, blocked with 5% nonfat milk for 1 hour at 
room temperature and probed with rabbit anti-TPO primary antibody (1:500, Abcam, 
Cambridge, MA) at 4ºC overnight. Blots were then incubated with horseradish 
peroxidase conjugated anti-rabbit secondary antibody (1:3000, The Jackson 
Laboratory, Bar Harbor, ME).  Blots were developed with use of an enhanced 
chemiluminescence detection kit (ECL, Amersham Pharmacia Biotech, Piscataway, 
NJ).  To ensure equal protein loading, a monoclonal anti-β-actin antibody (1:2000, 
Sigma-Aldrich, St. Louis, MO) was used.  At 72 hours following transfection with 
hTPO siRNA sequence 2, human TPO protein expression was reduced by 75% 
(Figure 6). 
 
      
Figure 6.  Validation of human thrombopoitein silencing at the protein level.  
Western blot analysis was used to validate effective human TPO (hTPO) 
knockdown with hTPO siRNA sequence 2 at the protein level.  A nontargeting 
siRNA sequence was used as control. 
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      Human- and murine-specific ELISAs for IL-6 were used to screen human and 
murine IL-6 siRNA sequences for efficacy of IL-6 gene silencing.  MOEC and 2774 
cells were transfected with siRNA directed against murine and human IL-6, 
respectively.  Cells were harvested at 24, 48, and 72 hour time points and lysed 
with modified radioimmunoprecipitation assay (RIPA) lysis buffer with 1x protease 
inhibitor (Roche, Mannheim, Germany) and 1 mM sodium orthovanadate for 20 
minutes on ice.  Cell lysate was centrifuged at 13,000 rpm for 20 min at 4ºC.  
Protein concentration was determined by a bicinchoninic acid protein assay reagent 
kit.  Fifty micrograms of protein from whole-cell lysate was used to perform ELISAs 
according to the manufacturer’s protocol.  After development of the colorimetric 
reaction, the absorbance at 450 nm was quantified by spectrophotometer and the 
absorbance readings were converted to pg/ml based upon standard curves 
generated with recombinant human or mouse recombinant cytokine.  At 72 hours, 
transfection with sequence 1 reduced human IL-6 protein expression by 60% and 
transfection with murine sequence 2 reduced murine IL-6 protein expression by 
70% compared to control siRNA (Figure 7a & b). 
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Figure 7.  Selection of effective siRNA sequences for targeting IL-6.  ELISA 
immunoassays were used to screen three candidate human IL-6 (hIL-6) (a) and 
murine IL-6 (mIL-6) (b) siRNA sequences.  A nontargeting siRNA sequence was 
used as control.         
 
      RT-PCR was used to screen murine G-CSF siRNA sequences for efficacy of G-
CSF gene silencing.  MOEC cells were harvested 24, 36, and 48 hours following 
transfection with murine G-CSF siRNA oligonucleotides.  RNA extraction and cDNA 
synthesis were performed as previously described.  PCR amplification was 
performed according to the following conditions:  94°C for 5 minutes for denaturing, 
followed by 32 cycles of melting at 94°C for 45 seconds and annealing-extending 
with Taq thermostable polymerase at 66°C for 60 seconds, followed by at final step 
A 
B 
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at 72°C for 10 minutes.  The primers used for PCR amplification were murine G-
CSF sense (5′-CTTCCCTGAGTGGCTGCTCT-3′) and antisense (5′-
AGCCCTGCAGGTACGAAATG-3′).  Amplified PCR products were analyzed by 
electrophoresis on 1.5% agarose gel with Tris-borate-EDTA buffer and visualized 
under UV light after staining with ethidium bromide.  Near complete silencing of 
murine GCSF transcript was achieved with sequence 1 (Figure 8). 
 
 
Figure 8.  Selection of effective siRNA sequences for targeting murine G-CSF.  
RT-PCR was used to screen three candidate murine G-CSF siRNA sequences 
(mGCSF 1-3).  A nontargeting siRNA sequence was used as control.         
 
      After selecting the most effective of three candidate siRNA oligonucleotides for 
targeting the human and mouse homologs of each cytokine, siRNA oligonucleotides 
were incorporated into chitosan nanoparticles (spherical, 100-200 nm size) for 
systemic in vivo delivery.  Here, we utilized chitosan because of its advantageous 
biological properties such as biodegradability and biocompatibility with regards to 
low immunogenicity and lack of toxicity (82).  Unpublished data from our laboratory 
also confirm highly efficient delivery of siRNA incorporated into chitosan 
nanoparticles into both tumor and tumor-associated endothelial cells (83).  Effective 
delivery of siRNA to endothelial cells was an important consideration for these in 
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vivo studies because vascular and liver sinusoidal endothelial cells are rich sources 
of G-CSF and TPO, respectively (84).  Additionally, immunohistochemical staining 
of patient and in vivo ovarian cancer specimens revealed high TPO expression by 
tumor-associated endothelial cells.  Chitosan (CH, molecular weight 50-190 kDa), 
sodium tripolyphosphate (TPP), and agarose were purchased from Sigma Co. (St. 
Louis, MO).  SiRNA/CH nanoparticles were prepared based on ionic gelation of 
anionic TPP and siRNA with cationic CH using a 3:1 ratio of CH:TPP.  Specifically, 
CH was dissolved in 0.25% acetic acid and nanoparticles spontaneously generated 
upon the addition of TTP (0.25% w/v) and siRNA (1 µg/µL) to CH solution under 
constant stirring at room temperature.  After incubating at 4ºC for 40 minutes, 
siRNA/CH nanoparticles were collected by centrifugation at 12,000 rpm for 40 
minutes at 4ºC.  The pellet was washed 3 times to remove unbound chemicals or 
siRNA and siRNA/CH nanoparticles were stored at 4ºC until used.   
      The effect of silencing TPO, IL-6, and G-CSF on thrombocytosis was evaluated 
in two orthotopic mouse models of ovarian cancer previously shown to consistently 
develop paraneoplastic thrombocytosis.  Nude mice were injected with either 
A2780ip2 (1x106 cells/0.2cc HBSS) or 2774 (2x106 cells/0.2cc HBSS) human 
ovarian cancer cells intraperitoneal.  After 3-4 weeks, mice had developed palpable 
tumors in the adnexa and/or omentum and were randomly allocated to one of 5 
treatment groups (n = 8 mice/group per cell line):  1) control siRNA/CH, 2) Hs + Mm 
IL-6 siRNA/CH, 3) Hs + Mm TPO siRNA/CH, 4) Mm G-CSF siRNA + control 
siRNA/CH, 5) combination IL-6 (Hs + Mm), TPO (Hs + Mm), and Mm G-CSF 
siRNA/CH.  Mice were treated by tail vein injection with 100 µL siRNA/CH 
nanoparticles which delivered 5µg siRNA per target every 72 hours for 1 week.  
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Mice were sacrificed 24 hours after the 3rd treatment following intracardiac stick to 
collect blood for determination of platelet counts by CBCs.  Tumor and ascites were 
carefully measured to ensure uniformity across treatment groups.  Since we 
previously showed that platelet counts correlate with tumor burden, we did not want 
differences in tumor burden between treatment groups to confound our results.                    
Statistical analyses 
      Details regarding statistical analyses and power considerations used to evaluate 
individual datasets are embedded in the corresponding methods sections above.  
Briefly, the Fisher’s exact test was used to test the associations between platelet 
count at the time of initial diagnosis and clinicopathologic variables with SAS.  
Kaplan-Meier survival curves were generated and compared using a 2-sided log-
rank statistic.  The Cox proportional hazards model was used for multivariate 
analysis.  Two-tailed Student’s t-test was used to test differences in sample means 
for data resulting from in vivo and in vitro experiments.  Pearson’s correlation 
coefficient was used to test associations between platelet counts, tumor weight, and 
number of intraperitoneal metastases in tumor- and ascites-bearing mice.  A p value 
< 0.05 was considered statistically significant.  To determine whether plasma 
thrombopoietic cytokine levels were associated with platelet count, we calculated 
Spearman’s r for each pairwise association and tested for a statistically significant 
difference from 0. With 150 patients we had 82% power to detect a correlation of 
magnitude 0.28 or higher using a 2-sided z-test with 1% statistical significance. 
Additionally, we used t-tests to determine whether thrombopoietic cytokines differ 
between patients with normal platelet counts and thrombocytosis.  We had 80% 
 46 
 
power to detect a difference of 0.6 standard units between groups using a 2-sided 
test with 1% statistical significance given a 30% prevalence rate of thrombocytosis.  
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Results 
Prevalence and clinical significance of thrombocytosis in epithelial ovarian 
carcinoma 
      To ascertain the prevalence and clinical significance of thrombocytosis in 
epithelial ovarian carcinoma, patient data were collected on 619 women from 4 U.S. 
centers and used to test associations between platelet count at the time of initial 
diagnosis, clinicopathologic factors, and outcome.  Mean platelet counts in women 
with and without thrombocytosis were 558,410/µL and 316,570/µL, respectively 
(Table 5). 
 
   Table 5. Platelet counts in patients with invasive ovarian cancer 
 
All Patients 
(N = 619) 
No Thrombocytosis 
(N = 427) 
Thrombocytosis 
(N = 192) 
Platelet Count 
   
N 619 427 192 
Mean (SD) 391.46 (135.71) 316.57 (70.14) 558.41 (90.01) 
Median 364 318 542 
Min – Max 107.00 - 937.00 107.00 - 450.00 451.00 - 937.00 
 
      The demographic characteristics of patients are embedded in Table 6.  Ninety-
two percent and 97% of patients had high stage (III-IV) and high grade (II-III) 
disease, respectively.  Seventy-seven percent had serous histology and 58% 
underwent optimal surgical cytoreduction.  Thirty-one percent of women had 
thrombocytosis at the time of initial diagnosis, which is considerably higher than the 
published prevalence of thrombocytosis in other solid malignancies (Table 7).   
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Table 6.  Associations between thrombocytosis (platelets > 450,000/µL) and 
clinicopathological variables 
Variable 
All Patients 
(N = 619) 
Platelets WNL 
(N = 427) 
Thrombocytosis 
(N = 192) p-value 
Age     0.15 
N 619 427 192  
Mean (SD) 60.68 (11.29) 61.15 (11.66) 59.63 (10.38)  
Median 60 60 60  
Min - Max 13.00 - 92.00 13.00 - 92.00 31.00 – 83.00  
Thromboembolism     0.008 
No Thromboembolism  189 (76.83%) 125 (82.78%) 64 (67.37%)  
Thromboembolism  57 (23.17%) 26 (17.22%) 31 (32.63%)  
Stage     <0.001 
Low Stage  52 (8.40%) 46 (10.77%) 6 (3.13%)  
High Stage  567 (91.60%) 381 (89.23%) 186 (96.88%)  
Grade     0.15 
Low Grade  21 (3.40%) 18 (4.22%) 3 (1.56%)  
High Grade  598 (96.60%) 409 (95.78%) 189 (98.44%)  
Histology     0.099 
Other Histology  143 (23.10%) 107 (25.10%) 36 (18.75%)  
Serous  476 (76.90%) 320 (74.94%) 156 (81.25%)  
Cytoreduction     0.51 
 Suboptimal 
Cytoreduction  236 (42.14%) 162 (41.22%) 74 (44.31%)  
Optimal Cytoreduction  324 (57.86%) 231 (58.78%) 93 (55.69%)  
CA-125     < 0.001 
N 335 242 93  
                      Mean (SD)    
 
2,220.40 
(21,158.98) 
2,481.41 
(24,853.64) 
1,541.20 
(2,568.12)  
Median 376 324 654  
Min - Max 7 - 385,378 7 -385,378.00 27 – 16,032  
White Blood Cells     0.002 
N 223 163 60  
Mean (SD) 7.97 (2.42) 7.80 (2.59) 8.42 (1.83)  
Median 7.9 7.5 8.6  
Min - Max 2.10 - 17.40 2.10 - 17.40 4.40 – 14.10  
Red Blood Cells     < 0.001 
N 220 161 59  
Mean (SD) 4.22 (0.63) 4.31 (0.66) 3.97 (0.46)  
Median 4.2 4.3 3.9  
Min - Max 3.10 - 9.90 3.10 - 9.90 3.12 – 5.14  
Hemoglobin     < 0.001 
N 222 162 60  
Mean (SD) 12.23 (1.63) 12.59 (1.58) 11.27 (1.38)  
Median 12.3 12.7 11.3  
Min - Max 7.40 - 17.00 8.90 - 17.00 7.40 – 14.80  
Hematocrit     < 0.001 
N 223 163 60  
Mean (SD) 36.56 (4.78) 37.59 (4.53) 33.76 (4.31)  
Median 36.8 38.1 34  
                       Min - Max 23.10 - 50.30 27.90 - 50.30 23.10 – 43.00  
 49 
 
   Table 7.  Prevalence of thrombocytosis in solid malignancies 
Malignancy # of 
patients 
Prevalence of 
Thrombocytosis 
Reference 
GBM 153 19% (85) 
H&N 270 7.2% (86) 
Breast 4300 3.7% (87) 
NSCLC 240 5.8% (88) 
Gastric 369 11.4% (32, 89) 
HCC 1154 2.7% (90) 
Colon 198 12.1% (10, 11, 91) 
RCC 700 25% (10, 92) 
RCC* 804 7.8% (93) 
Cervix 623 9.5% (94) 
Vulvar 201 15.5% (95) 
Endometrial 135 14% (96) 
  *used ≥ 450,000/µL, others used ≥ 400,000/µL 
 
      Regarding other blood count parameters, mean leukocyte count was 
significantly higher in women with thrombocytosis (8.42 ± SD 1.83 x 103/µL versus 
7.8 ± SD 2.59 x 103/µL, p=0.0021) and thrombocytosis was significantly associated 
with mild anemia (mean Hgb 11.27 ± SD 1.38 g/dL versus 12.59 ± SD 1.58 g/dL, 
p<0.001; Figure 9). 
   
 
Figure 9.  Changes in other CBC parameters according to platelet count.  
Mean white blood cell count (WBCC) and hemoglobin (Hgb) ± SD in patients with 
platelet counts within normal range and in patients with thrombocytosis. * p < 0.01. 
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      Univariate analyses testing correlations between platelet count and 
clinicopathologic variables known to impact disease specific survival revealed that 
women with thrombocytosis were significantly more likely to have advanced stage 
disease compared to women with normal platelet counts (p=<0.001; Table 6).  
Thrombocytosis was also significantly associated with poor median progression-free 
and overall survival.  Median time to recurrence among women who presented with 
thrombocytosis was 0.94 years compared to 1.35 years for women with normal 
platelet counts (p<0.001, Figure 10a).  Median overall survival among patients with 
thrombocytosis was 2.62 years compared to 4.65 years for patients with normal 
platelet counts (p<0.001; Figure 10b). 
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Figure 10.  Thrombocytosis and survival.  Kaplan-Meier analysis evaluating the 
effect of thrombocytosis on disease-free interval (a) and overall survival (b) in 
ovarian cancer patients. 
 
      On the basis of these findings, we assessed whether there was an independent 
association between thrombocytosis and prognosis.  In a multivariate survival 
analysis using a Cox proportional hazards model adjusting for age, disease stage, 
tumor grade, histological type, and extent of surgical cytoreduction, thrombocytosis 
remained an independent predictor of decreased progression free (p<0.001) and 
overall survival (p<0.001).  In this model, patients who presented with 
thrombocytosis had a 1.87–fold increased risk of death compared to patients with 
normal platelet counts (Tables 8a and b).   
 
A 
B 
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   Table 8a.  Multivariate Cox proportional hazards analysis of 
   prognostic factors on progression free survival 
Variable HR p-value 95% CI 
Thrombocytosis 1.51 <0.001 1.22 - 1.88 
Age 1.01 0.15 1.00 - 1.02 
Stage III/IV 4.92 < 0.001 2.93 - 8.25 
High Grade 0.89 0.73 0.46 - 1.72 
Serous Histology 1.48 0.004 1.13 - 1.94 
Suboptimal 
Cytoreduction 1.13 0.24 0.92-1.40 
 
   Table 8b.  Multivariate Cox proportional hazards analysis of  
   prognostic factors on overall survival 
Variable HR p-value 95% CI 
Thrombocytosis 1.87 < 0.001 1.44 - 2.44 
Age 1.00 0.51 0.99 - 1.02 
Stage III/IV 4.19 < 0.001 2.05 - 8.55 
High Grade 2.80 0.05 1.02 - 7.70 
Serous Histology 1.30 0.11 0.94 - 1.80 
Suboptimal 
Cytoreduction 1.39 0.01 1.07-1.80 
 
      Given that vascular thromboembolism (VTE) contributes significantly to the 
morbidity of malignancy and that platelets play a major role in the initiation and 
growth of thrombi, we determined whether thrombocytosis was associated with 
increased incidence of VTE in a subset of 246 ovarian cancer patients.  We found 
that patients with thrombocytosis had a 2.3–fold increased risk of VTE compared to 
individuals with normal platelet counts (p<0.01).  Among the 57 (23.2%) women 
who experienced VTE, 28 cases were simultaneous with a new diagnosis of ovarian 
carcinoma and 29 cases transpired during the subsequent course of disease.  
Proportional hazards models that included a term for VTE suggested that 
thrombocytosis is an independent predictor of decreased time to recurrence and 
increased mortality in women who do develop a blood clot, but that mortality due to 
thrombotic complications alone was not significant (Tables 9a and b).       
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   Table 9a.  Multivariate Cox proportional hazard analysis of   
   prognostic factors including VTE on progression free survival   
Variable HR p-value 95% CI 
Thrombocytosis 1.92 <0.001 1.32 - 2.78 
VTE 1.03 0.90 0.68 - 1.56 
Age 1.01 0.24 0.99 - 1.03 
Stage III/IV 6.16 0.02 1.28 - 29.58 
High Grade 0.28 0.19 0.04 - 1.89 
Serous Histology 2.41 0.02 1.16 - 5.04 
Suboptimal 
Cytoreduction 0.92 0.66 0.64-1.32 
 
   Table 9b.  Multivariate Cox proportional hazard analysis of  
   prognostic factors including VTE on overall survival   
Variable HR p-value 95% CI 
Thrombocytosis 1.84 0.004 1.21 - 2.80 
VTE 0.89 0.68 0.52 - 1.52 
Age 1.00 0.93 0.98 - 1.02 
Stage III/IV 1.52 0.50 0.45 - 5.18 
High Grade 1.42 0.66 0.30 - 6.66 
Serous Histology 1.05 0.88 0.56 - 1.97 
Suboptimal 
Cytoreduction 1.14 0.52 0.76-1.73 
 
Paraneoplastic thrombocytosis is recapitulated in mouse models of ovarian 
carcinoma and other solid malignancies 
      To assess the relative utility of our existing orthotopic mouse models of ovarian 
cancer for further investigating clinical observations related to paraneoplastic 
thrombocytosis, we compared platelet counts between healthy control mice and 
mice bearing invasive ovarian cancer with and without large volume ascites.  We 
found that compared to controls (mean 1.05 ± SEM 0.05 x 106/µL), tumor-bearing 
mice had a 31% increase in platelets (mean 1.37 ± SEM 0.07 x 106/µL, p=0.003) 
and that platelet counts more than doubled in tumor-bearing mice with ascites 
(mean 2.38 ± 0.24 x 106/µL, p=0.001; Figure 11a).  Furthermore, platelet counts 
strongly correlated with tumor burden (r=0.78, p<0.01) and number of 
intraperitoneal metastases (r=0.65, p<0.01; Figure 11b). 
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Figure 11.  Platelet counts and correlation with tumor burden in orthotopic 
mouse models of ovarian cancer.  Platelet counts were measured in whole blood 
collected from healthy control mice as well as orthotopic mouse models of ovarian 
cancer bearing invasive tumors with (2774) and without (HeyA8 and A2780ip2) 
large volume ascites (a).  Tumor weight and number of intraperitoneal metastases 
were correlated with platelet counts in the 2774 model (b).   
 
      We observed a non-significant increase in leukocytes and reduction in red blood 
cell mass in mice with invasive ovarian tumors ± ascites compared to healthy 
controls (Figure 12a & b).   
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Figure 12.  Changes in other CBC parameters in orthotopic mouse models of 
ovarian cancer.  Results represent mean white blood cell count (WBCC, a) and 
mean red blood cell count (RBCC, b) ± SEM in orthotopic mouse models of ovarian 
cancer bearing invasive tumors with (2774) and without (HeyA8 and A2780ip2) 
large volume ascites.   
 
      To determine whether thrombocytosis is idiosyncratic to our orthotopic models 
of ovarian cancer, we also assessed platelet counts in 2 syngeneic mouse models 
of ovarian cancer.  Both syngeneic models developed significant thrombocytosis.  
Platelet counts were increased by 64% and 59% (p<0.05) in mice bearing invasive 
tumors derived from IG10 and ID8VEGF164 cells, respectively (Figure 13a).  To 
establish the generalizability of our finding of thrombocytosis in mouse models of 
ovarian cancer to mouse models of other solid malignancies, we quantified platelets 
in orthotopic mouse models of breast (GILM2 cell line) and uterine cancer (Ishikawa 
cell line) as well as in a human pancreatic tumor xenograft mouse model.  Platelet 
counts were not elevated over baseline in mice with GILM2 breast tumors, but were 
significantly increased in Ishikawa uterine (30%, p<0.05) and pancreatic cancer 
models (39%, p<0.05; Figure 13b).   
A B 
 56 
 
 
Figure 13.  Platelet counts in syngeneic mouse models of ovarian cancer and 
mouse models of other solid malignancies.  Platelet counts were evaluated 2 
syngeneic mouse models of ovarian cancer (a) and in orthotopic mouse models of 
metastatic breast and uterine cancer as well as in a heterotopic human pancreatic 
xenograft model (b).  Bars represent mean ± SEM.  † indicates p < 0.05.     
 
      Given that thrombocytosis was consistently detected in mice with large volume 
disease, we conducted a time course study to characterize the onset and 
development of thrombocytosis in an orthotopic mouse model of ovarian cancer by 
tracking platelet counts with disease progression.  Bioluminescence imaging was 
used to detect disease until it was palpable by physical exam (day 22).  We found 
that platelets began to appreciably rise when mean tumor burden exceeded 0.62 
cm, which corresponded to the point at which disease was reliably detectable on 
exam.  Platelet counts continued to increase with disease progression and were 
highest when mice became moribund (Figure 14). 
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Figure 14.  Time course delineating the onset and progression of 
thrombocytosis in ovarian cancer-bearing mice.  Bioluminescence imaging was 
used to detect HeyA8-Luc tumor growth until day 22, when tumors were palpable by 
physical exam.  Tumor burden represents mean tumor weight in grams ± SEM 
(black bars, left-hand y-axis).  Platelet count is reported as mean % increase in 
platelet count compared to control (bars with cross hatching, right-hand x-axis).        
   
Platelets extravasate into tumors and ascites 
      Several mechanisms have been proposed to explain how platelets facilitate the 
growth and dissemination of malignancy.  Platelets may adhere to circulating tumor 
cells and help them to lodge in the microvasculature where they can form 
intravascular colonies and/or infiltrate into target organs.  Additionally, oncogenic 
and angiogenic factors released by platelets may support cancer cell survival, 
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proliferation, and invasion as well as angiogenesis.  Given that many solid 
malignancies, including ovarian cancer, do not have a well defined hematogenous 
phase, we hypothesized that platelets extravasate into the tumor bed where they 
can subsequently exert direct effects on cancer cells.  To test this hypothesis, we 
isolated platelets from a transgenic mouse expressing yellow fluorescent protein 
(YFP) under the control of the platelet specific PF4 promoter and transfused them 
into ID8VEGF164 tumor-bearing C57BL/6 mice (Figure 15a).  Tumors were resected 1 
hour following YFP-platelet transfusion and intravital fixation.  To aid in localizing 
YFP-platelets in tumor sections, immunofluorescent staining with Hoechst and for 
CD31 antigen was performed to label nuclei and the tumor vasculature, 
respectively.  Within 1 hour of transfusion, YFP-labeled platelets were present in the 
tumor bed, primarily in a peri-vascular location (Figure 15b).  YFP-labeled platelets 
were also found free-floating and adhered to cells in ascites within 1 hour of 
transfusion into tumor-bearing recipient mice (Figure 15c). 
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Figure 15.  Platelet extravasation into solid tumor and ascites.  The 
methodology used to determine if platelets extravasate into solid tumor and ascites 
is depicted in panel (a).  Platelets isolated from transgenic mice expressing yellow 
fluorescent protein (YFP) under the control of the platelet specific PF4 promoter 
were transfused into mice with invasive ovarian cancer and ascites.  Tumor was 
resected one hour following intravital fixation.  To localize YFP-platelets (yellow) in 
tumor sections, immunofluorescent staining with Hoechst and for CD31 antigen was 
performed to label nuclei (blue) and the tumor vasculature (red), respectively (b).  
Whole mounts of ascites removed by paracentesis prior to intravital fixation were 
examined with fluorescent (middle panel, 200x) and confocal microscopy (right 
panel 400x) to visualize YFP-platelets adhered to ascites cells (white arrows, c). 
     
Anti-tumor effects of platelet depletion  
      To evaluate the biological effect of platelet depletion on tumor growth, we used 
an anti-platelet antibody (APA) directed against platelet glycoprotein Ibα receptor to 
decrease platelets in an orthotopic mouse model of ovarian cancer.  The rationale 
for selecting this approach as well as the antibody dose and treatment schedule 
used for this investigation are addressed in the methods section.  After conducting 
preliminary experiments to characterize the activity and specificity of the antibody, a 
therapy experiment was initiated.  Mice inoculated with A2780ip2 ovarian cancer 
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cells were treated with either 0.5 µg/g anti-GP1bα antibody or control IgG by tail 
vein injection every 4 days until they became moribund.  Tumor weight was 
recorded at the time of necropsy.  Overall, ovarian tumors resected from APA 
treated mice appeared grossly hemorrhagic and smaller than those resected from 
mice treated with control IgG (Figure 16).   
 
 
Figure 16.  Macroscopic appearance of A2780ip2 tumors resected from mice 
treated with control IgG (top panel) and anti-platelet antibody (bottom panel).   
 
      Antibody mediated platelet depletion inhibited tumor growth by 50% compared 
to control IgG (p<0.05; Figure 17a).  To investigate the underlying mechanisms 
accounting for the anti-tumor effect of platelet depletion in our model, we performed 
immunohistochemical staining for Ki67 and CD31 antigens to ascertain the 
proliferative index and microvessel density of tumor specimens, respectively.  
Compared to control IgG, antibody mediated platelet depletion resulted in a 44% 
decrease in tumor cell proliferation and a 51% reduction in microvessel density 
(p<0.001; Figures 17b & c).  To further investigate the effects of platelet depletion 
on the tumor vasculature, we examined microvessel pericyte coverage with dual 
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immunohistochemical staining for CD31 and desmin.  Given that pericytes are 
PDGF-dependent mesenchymal cells that support and stabilize small blood vessels 
and that PDGF is one of the principal cytokines released by platelets, we 
hypothesized that platelet depletion would have a detrimental effect on microvessel 
pericyte coverage (97, 98).  We found that platelet depletion reduced pericyte 
coverage by 60% (p<0.001).  Tumor microvessels were predominantly devoid of 
pericytes and existing pericytes appeared loosely attached (Figure 17d).  
Considering that pericytes support endothelial cell survival and that tumor cell 
survival depends on an intact vascular network, we next determined whether 
platelet depletion was associated with increased tumor and endothelial cell 
apoptosis using dual CD31 staining and TUNEL labeling.  Compared to control IgG, 
antibody mediated platelet depletion resulted in a 4- and 8-fold increase in tumor 
and endothelial cell apoptosis, respectively (p<0.01; Figure 17e).  Thus, the anti-
tumor effect of platelet depletion was likely multi-factorial and could be attributed to 
decreased tumor cell proliferation, microvessel density, and pericyte coverage as 
well as increased tumor and endothelial cell apoptosis.   
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Figure 17.  In vivo effects of platelet depletion on tumor growth, cell 
proliferation, microvessel density, pericyte coverage, and apoptosis.  In vivo 
effects of platelet depletion were examined using an anti-platelet antibody (APA, 
anti-mouse glycoprotein 1bα) to reduce platelets by 50%.  Nude mice were injected 
with A2780ip2 ovarian cancer cells i.p. and treated with either 0.5 µg/g APA (n=10) 
or PBS vehicle control (n=10) i.v. every 4 days until they became moribund.  Mean 
tumor weight ± SEM (left panel) and corresponding tumor weight distributions are 
shown (right panel).  Proliferation index (b) and tumor vascularity (c) were assessed 
with immunohistochemical staining for Ki67 and CD31 antigen, respectively.  
Pericyte coverage was evaluated using dual immunofluorescence staining for CD31 
(endothelial cell marker, red) and desmin (pericyte marker, green, d).  Tumor and 
endothelial cell apoptosis was assessed with dual immunofluorescence staining for 
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CD31 (red) and TUNEL (apoptosis marker, green).  Apoptotic tumor cells have 
green fluorescent nuclei where as colocalization of endothelial cell undergoing 
apoptosis shows yellow fluorescence (white arrows, e).  Representative 
photomicrographs appear to the left of the graphs.  Graphs represent mean ± SEM 
calculated for 5 random x200 HPF.  † indicates p < 0.05 and * indicates p < 0.01.      
   
Functional effects of platelets on ovarian cancer cell proliferation, survival and 
migration 
      Given our in vivo data suggesting that platelet depletion inhibits tumor growth by 
several mechanisms including decreased tumor cell proliferation and increased 
apoptosis, we subsequently explored the stimulatory effects of platelets from tumor-
bearing mice on ovarian cancer cells in vitro.  Specifically, in vitro effects of plasma-
purified platelets on ovarian cancer cell migration, proliferation, and docetaxel-
induced apoptosis were evaluated using two-chamber chemotaxis and BrdU-PI flow 
cytometric assays.  Platelets significantly stimulated A2780ip2, HeyA8, and 2774 
ovarian cancer cell migration.  The mean number of migrating A2780ip2 (141.2 ± 
9.6/HPF), HeyA8 (147.9 ± 9.8/HPF), and 2774 (113.3 ± 6.2/HPF) cells in response 
to platelets was significantly higher than their chemotactic response to vehicle alone 
(53.2-55 ± 4.4-5.7/HPF, p<0.01; Figure 18).   
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Figure 18.  Effect of platelets on ovarian cancer cell migration in vitro.  Results 
represent mean change in number of cells migrating in response to platelets relative 
to vehicle control ± SEM of triplicate experiments.  Representative images of 
migrated A2780ip2, HeyA8, or 2774 cells in response to platelets or vehicle control 
are included.  * indicates p < 0.01.       
 
      The impact of platelets on tumor cell proliferation and survival was next 
evaluated in a panel of 6 ovarian cancer cell lines.  For proliferation assays, cells 
were co-cultured with plasma-purified platelets from tumor-bearing mice 
(10x106/mL) or vehicle alone for 24 hours.  To evaluate the effect of platelets on 
ovarian cancer cell survival, similar co-culture conditions were used except cells 
were concurrently treated with or without 0.5 nM docetaxel for 72 hours.  Cell 
proliferation and death were measured by flow cytometric analysis of BrdU 
incorporation and PI staining, respectively.  Platelets induced proliferation and 
protected against cytotoxicity due to docetaxel treatment in every cell line except 
2774.  Specifically, platelets significantly increased mean percent BrdU positive 
A2780ip2 cells by 16.4 ± 1.2% (4.1-fold increase, p=0.006), HeyA8 cells by 19.7± 
3.4% (2.2-fold increase, p=0.03), SKOV3ip1 cells by 23.9 ± 1.4% (3.4-fold increase, 
p=0.004), OVCA433 cells by 8.8 ± 0.2% (1.3-fold increase, p=0.02), and ES2 cells 
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by 15.6 ± 1% (3-fold increase, p=0.008; Figure 19a).  The most robust anti-
apoptotic effects of platelets were observed in SKOV3ip1 and ES2 cell lines.  
Platelets significantly decreased mean percent PI positive SKOV3ip1 cells by 15.5 ± 
5% (2-fold decrease, p=0.03) and ES2 cells by 19.2 ± 2.6% (2-fold decrease, 
p<0.001; Figure 19b).   
 
       
Figure 19.  Effect of platelets on ovarian cancer cell proliferation and 
apoptosis in vitro.  Effect of platelets on ovarian cancer cell proliferation (a) and 
apoptosis (b) was assayed using flow cytometry for BrdU labeling and PI staining, 
respectively.  Results represent mean change in percent positively staining cells 
over vehicle control ± SEM of triplicate experiments.  † represents p < 0.05 and * 
represents p < 0.01. 
      
      Given that platelets stimulated proliferation and conferred resistance to 
docetaxel-induced cytotoxicity in every cell line except 2774 and that these 
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observed effects could be due at least in part to platelet derived growth factors, we 
looked for differences in growth factor receptor expression among the ovarian 
cancer cell lines used in these assays.  Relative to the other ovarian cancer cell 
lines, 2774 has the lowest PDGFRα protein expression (Figure 20a).  Knowing that 
receptor tyrosine kinase receptors contribute to chemoresistance in malignancies 
and finding that PDGFRα expression is appreciably elevated in the taxane-resistant 
cell lines HeyA8-MDR and SKOV3-TR relative to their respective parental lines 
(Figure 20b), raised the question of PDGFRα involvement in platelet-mediated 
ovarian cancer cell taxane-resistance.   
 
 
 
Figure 20.  Platelet derived growth factor alpha (PDGFRα) expression in 
ovarian cancer cell lines.  Western blot analysis was used to evaluate PDGFRα 
expression in a panel of human ovarian cancer cell lines (a) and in the taxane-
resistant cell lines HeyA8-MDR and SKOV3-TR compared to their respective 
parental lines (b).  PDGFRα is a dimer formed by 150 and 170 kDa subunits.   
 
      To investigate the contribution of PDGFRα to platelet-induced resistance to 
docetaxel, we pre-treated SKOV3ip1 cells with IMC-3G3, a fully-humanized anti-
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PDGFRα antibody, prior to adding platelets +/- docetaxel.  Treatment with IMC-3G3 
alone was not significantly cytotoxic.  The addition of platelets reduced the cytotoxic 
effect of docetaxel by 17%, which was consistent with our previous findings.  
However, IMC-3G3 completely abrogated the chemoprotective effect of platelets, 
suggesting that blocking PDGFRα might be one potential strategy for inhibiting the 
stimulatory effect of platelets on ovarian cancer cell survival and for combating 
resultant chemoresistance (Figure 21). 
 
         
Figure 21.  Effect of fully humanized anti-PDGFRα antibody, IMC-3G3, on 
platelet induced taxane resistance.  Ovarian cancer cells were pretreated with 
100 µg/mL IMC-3G3 or PBS vehicle for 2 hours prior to adding platelets ± 0.5 nM 
docetaxel.  Apoptosis was assessed using flow cytometry to detect PI staining.   
 
Megakaryopoiesis and thrombopoiesis in response to specific cytokines is a 
potential underlying mechanism of paraneoplastic thrombocytosis 
      To this point the underlying etiology of paraneoplastic thrombocytosis has 
remained unknown.  Under normal physiological conditions, thrombopoiesis is 
regulated by several pleiotrophic growth factors and cytokines that influence various 
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steps in the process, starting with megakaryocyte progenitor proliferation and 
proceeding through maturation to the eventual release of platelets into circulation 
(99, 100).  While there have been some studies examining the link between 
perturbations in the humoral regulation of thrombopoiesis and thrombocytopenia, 
there has not been a concerted effort to explore the role of humoral factors in the 
development of thrombocytosis associated with malignancy.  We hypothesized that 
factors produced by cancer cells, the tumor vasculature, and/or host tissues 
stimulate megakaryo- and thrombopoiesis, resulting in paraneoplastic 
thrombocytosis.  To test this hypothesis, we first quantified megakaryocytes in bone 
marrow and spleens from orthotopic mouse models of ovarian cancer that 
consistently develop paraneoplastic thrombocytosis.  These sites were selected 
because hematopoiesis is known to occur primarily in the medullary cavity of long 
bones and spleen in the adult mouse.  We found that the mean number of 
medullary megakaryocytes per HPF was significantly increased in tumor-bearing 
mice (mean 4.8 ± SEM 0.4) compared to controls (mean 2.6 ± SEM 0.3, p<0.01).  
Tumor-bearing mice with ascites had a 2.7-fold increase in medullary 
megakaryocytes (mean 6.9 ± SEM 0.4) compared to controls (p<0.01).  Significant 
megakaryocyte expansion was also observed in the spleen.  Compared to controls 
(mean 0.84 ± SEM 0.3), splenic megakaryocytes were increased 7-fold and 13-fold 
in tumor-bearing mice (mean 6.0 ± SEM 0.9, p<0.01) and tumor-bearing mice with 
ascites (mean 11.2 ± SEM 0.8, p<0.01), respectively (Figure 22).  Mean platelet 
counts across control and tumor-bearing mice ± ascites strongly correlated with 
mean megakaryocyte counts in the spleen and bone marrow (r=0.95, p<0.05).  
Given reports of extramedullary hematopoiesis in the adult mouse liver (101) and of 
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mature megakaryocytes migrating from the marrow to the pulmonary capillary bed 
where they release platelets (102, 103), we also examined liver and lung sections 
from these mice.  Megakaryocytes were not present in hepatic and pulmonary 
tissues (data not shown). 
   
 
Figure 22.  Medullary and splenic megakaryocyte counts.  Megakaryocytes 
(Mk) were enumerated in the bone marrow and spleen of healthy control (NCr-nu), 
tumor-bearing (A2780ip2 orthotopic model), and tumor- & ascites-bearing mice 
(2774 orthotopic model).  Graphs represent the mean number of megakaryocytes 
per 5 randomly selected x200 high power fields (HPF) ± SEM.  * indicates p < 0.01.  
Representative photomicrographs of megakaryocyte (black arrows) density in bone 
marrow (top panel) and spleen (bottom panel) from healthy control, tumor-bearing, 
and tumor- & ascites-bearing mice are included. 
   
      Based on finding medullary and splenic megakaryocyte hyperplasia in mice that 
develop paraneoplastic thrombocytosis in response to orthotopic human ovarian 
cancers, we next explored the expression of key factors implicated in megakaryo- 
 70 
 
and thrombopoiesis.  Given that TPO is the primary growth factor responsible for 
megakaryocyte development and platelet production (43, 104), we first assessed 
ovarian cancer cell TPO expression in vitro and in vivo.  Thrombopoietin transcript 
was detected in ovarian cancer cells in vitro (Figure 23a) and high cytoplasmic TPO 
protein expression was observed in A2780ip2, HeyA8, and 2774 in vivo tumor 
specimens (Figure 23b).   
 
 
Figure 23.  In vitro and in vivo ovarian cancer cell thrombopoietin expression.  
Thrombopoietin mRNA expression was assessed in duplicate in vitro cultures of 
A2780ip2 and 2774 human ovarian cancer cells using RT-PCR (a).  Thrombopoietin 
protein expression in in vivo specimens of A2780ip2, HeyA8, and 2774 tumors was 
evaluated using immunochemistry (b). 
 
      These findings suggest that ovarian cancer cells can be an ectopic source of 
TPO. Under physiological conditions, TPO is constitutively produced by hepatic 
parenchymal and sinusoidal endothelial cells and TPO levels are largely determined 
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by platelet and megakaryocyte TPO receptor-mediated internalization. This 
establishes an autoregulatory loop where in blood and marrow levels of TPO are 
inversely related to platelet and megakaryocyte numbers (105).  Although hepatic 
TPO production is generally considered to be fixed, we speculated that hepatic TPO 
production might increase in response to other cytokines, such as IL-6, elaborated 
by ovarian cancer cells.  Ovarian cancer cell secretion of IL-6, particularly in 
response to stress hormones, has been previously characterized by our laboratory 
(106).  IL-6 acts directly as a megakaryocyte maturation factor, but its 
thrombopoietic effect is thought to be indirect through increasing TPO gene 
transcription in the liver (44).  When we compared TPO mRNA levels in liver 
harvested from normal mice and from ovarian cancer-bearing mice, we consistently 
found higher TPO transcript levels in livers from ovarian cancer-bearing mice 
(Figure 24).  Whether increased IL-6 in tumor-bearing mice accounts for this finding 
remains to be determined.    
 
 
Figure 24.  Hepatic thrombopoietin transcript levels.  RT-PCR was used to 
assess hepatic thrombopoietin (TPO) mRNA levels in normal nude mice (n = 3) and 
ovarian cancer-bearing mice (n = 5).  
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Regardless, both ectopic tumor and super-physiologic hepatic TPO production 
might be responsible for high circulating TPO levels when they should otherwise be 
low in the context of thrombocytosis.   
      To assess the reproducibility of these findings in ovarian cancer patients with 
paraneoplastic thrombocytosis, we checked our clinical dataset for women who 
underwent bone marrow biopsy.  Since ovarian cancer patients rarely have 
indications for bone marrow biopsies, we were only able to identify a handful of 
patients.  Two patients that had thrombocytosis at the time of bone marrow biopsy 
also had megakaryocyte hyperplasia on pathology report.  The remaining patients 
either had normal platelet and megakaryocyte counts or thrombocytopenia and 
megakaryocyte hypoplasia.  The left panel of figure 25 is a representative image of 
bone marrow from a patient reported to have increased numbers of mature 
megakaryocytes, thrombocytosis (platelet count of 504 x 103/µL), and recent VTE.  
The right panel of figure 25 is a representative image of bone marrow from a patient 
about to start her fourth line of chemotherapy with reported megakaryocyte 
hypoplasia and thrombocytopenia (platelet count of 127 x 103/µL). 
   
 
Figure 25.  Bone marrow aspirates from patients with epithelial ovarian 
cancer.  Representative photomicrographs of bone marrow aspirates from ovarian 
cancer patients reported to have increased numbers of mature megakaryocytes (left 
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hand panel) and megakaryocyte hypoplasia (right hand panel).  Black arrows point 
to megakaryocytes.   
 
Although numbers are too small to make any definitive conclusion, this at least 
provides some anecdotal evidence that platelet counts may be related to the 
abundance of bone marrow megakaryocytes in ovarian cancer patients as well.  
Immunohistochemical staining for megakaryocyte markers revealed absence of 
megakaryocytes in spleens from ovarian cancer patients who had thrombocytosis 
prior to primary tumor reductive surgery which necessitated splenectomy (Figure 
26).  This finding was not unexpected given that the spleen is not known to be a 
hematopoietic organ in adult humans as it is in mice.     
 
 
Figure 26.  Examination of ovarian cancer patient spleens for 
megakaryocytes.  Representative immunohistochemical staining of spleens 
resected from ovarian cancer patients with thrombocytosis at the time of primary 
tumor reductive surgery for megakaryocyte and platelet markers CD42b (left hand 
panel) and CD61 (right hand panel) revealed the presence of platelets and the 
absence of megakaryocytes.   
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      To date, three tumor types have been reported to produce TPO: 
hepatoblastoma, hepatocellular carcinoma, and ovarian carcinoma.  It is not 
surprising that hepatoblastoma and hepatocellular carcinoma produce high levels of 
TPO since the liver is the dominant physiological source of TPO.  Furuhashi and 
colleagues published the only case report of an extrahepatic TPO-producing tumor, 
an ovarian carcinoma, over a decade ago (107).  Since, there have been no follow-
up studies examining TPO in ovarian carcinoma despite the high prevalence of 
thrombocytosis in women with advanced ovarian cancer.  Here, we show that 
ovarian carcinomas from women with thrombocytosis at the time of primary tumor 
reductive surgery consistently express high cytoplasmic levels of TPO (Figure 27 
cases 2-5).  Cases 4 and 5 also demonstrate the novel finding of TPO expression in 
tumor-associated endothelial cells.  On the contrary, we found that ovarian 
carcinomas from patients with normal preoperative platelet counts express relatively 
low or no TPO (Figure 27, case 1). 
 
 
Figure 27.  Thrombopoietin protein expression in patient specimens of serous 
papillary ovarian carcinoma.  Representative immunohistochemical staining for 
thrombopoietin in ovarian carcinomas from a patient with a normal platelet count 
(case 1) and patients with thrombocytosis (cases 2-5) is shown.  Tumor and tumor 
associated endothelial cells (black arrows) in specimens from patients with 
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thrombocytosis express high levels of thrombopoietin.  Preoperative platelet counts 
appear in parentheses below the photomicrographs. 
   
      While TPO is considered the primary physiologic regulator of platelet 
production, multiple pleiotropic growth factors and cytokines act synergistically on 
hematopoietic progenitors to promote the growth and maturation of megakaryocytes 
as well as the enumeration of platelets.  In order to identify the relevant humoral 
factors associated with thrombocytosis in ovarian cancer patients using a high 
through-put modality, we quantified expression levels of factors known to be 
implicated in megakaryo- and thrombopoiesis (Table 3) in plasma samples from 150 
patients with high grade, advanced stage epithelial ovarian carcinoma using a 
multiplex bead-based immunoassay.  Thirty-one percent of the patients included in 
this analysis had thrombocytosis, independently validating the prevalence of 
thrombocytosis we found in our earlier clinical dataset.  Platelet counts significantly 
correlated with plasma levels of IL-6 (rs = 0.4, p<0.0001) and TPO (rs = 0.3, 
p<0.0001, Table 10, Figure 28).   
      Table 10.  Spearman’s correlation of  
      platelet counts with plasma cytokine  
      levels in 150 ovarian cancer patients 
Cytokine Correlation p-value 
IL-6 0.37 < 0.0001 
TPO 0.29 0.0003 
G-CSF 0.16 0.0565 
IL-3 0.16 0.0570 
SCF 0.12 0.1505 
IL-1α 0.06 0.4968 
IL-11 0.05 0.5299 
GM-CSF 0.04 0.5880 
FLT3 Ligand -0.10 0.2335 
IL-4 -0.02 0.8361 
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Figure 28.  Spearman’s correlation of plasma IL-6 (a) and TPO (b) levels  
with platelet counts in 150 ovarian cancer patients. 
 
      When we tested differences in plasma cytokine levels between patients with 
normal platelet counts and thrombocytosis, we found that plasma levels of IL-6, 
TPO, and granulocyte colony-stimulating factor (G-CSF) were significantly elevated 
in patients with thrombocytosis.  Specifically, patients with thrombocytosis had a 
mean plasma IL-6 level of 33.42 pg/mL compared to 13.71 pg/mL for patients with 
normal platelet counts (p<0.0001).  Mean plasma TPO levels were 34.43 pg/mL and 
16.2 pg/mL for patients with thrombocytosis and normal platelet counts, respectively 
(p = 0.0003).  Additionally, mean plasma G-CSF levels were 88.8 pg/mL and 49.02 
pg/mL for patients with thrombocytosis and normal platelet counts, respectively (p = 
0.03, Table 11, Figure 29).  While plasma levels of IL-4 did not significantly differ 
between patients with normal platelet counts (mean 1.32 ± 12.91 pg/mL) and 
thrombocytosis (0.13 ± 0.87 pg/mL), IL-4 levels were lower in patients with 
thrombocytosis.  This finding is of interest because IL-4 is one of few factors 
reported to inhibit megakaryopoiesis (46). 
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Table 11.  Wilcoxon rank sum test testing differences in plasma cytokine levels 
(pg/mL) between patients with normal platelet counts and thrombocytosis 
 Normal platelet counts Thrombocytosis 
Cytokine 
Mean 
(SD) Median Min - Max 
Mean 
(SD) Median Min – Max P value 
IL-6 
13.71 
(25.61) 5.40 0 - 198.43 
33.42 
(74.30) 15.50 0.52 - 500.48 < 0.0001 
TPO 
16.2 
(42.61) 3.37 0 - 361.53 
34.43 
(119.10) 16.96 0 - 819.75 0.0003 
G-CSF 
49.02 
(62.03) 25.97 0 - 403.37 
88.8 
(127.53) 44.17 3.05 - 709.22 0.0255 
IL-3 
0.76 
(1.27) 0.06 0 - 8.21 
1.79 
(4.15) 0.45 0 – 21.60 0.1275 
SCF 
8.9 
(13.15) 3.97 0 - 82.13 
10.09 
(11.21) 7.23 0 – 43.65 0.3070 
IL-11 
10.34 
(29.17) 0 0 - 197.23 
15.11 
(45.10) 0 0 - 290.13 0.3627 
FLT3- 
Ligand 
21.3 
(95.35) 0 0 - 917.89 
5.12 
(15.80) 0 0 – 87.55 0.2481 
IL-1α 
41.51 
(287.84) 0 0 – 2,929.08 
11.34 
(19.19) 0 0 – 73.51 0.7635 
GM-CSF 
18.13 
(60.06) 0 0 - 366.90 
11.5 
(40.69) 0 0 - 270.08 0.7963 
IL-4 
1.32 
(12.91) 0 0 - 131.60 
0.13 
(0.87) 0 0 - 5.94 0.8008 
 
 
Figure 29.  IL-6, thrombopoietin, and G-CSF plasma levels in ovarian cancer 
patients.  Graphs show mean differences in plasma IL-6, TPO, and G-CSF levels in 
patients with normal platelet counts (light bars) and patients with thrombocytosis 
(dark bars). * indicates p < 0.01 and † indicates p < 0.05.        
      Next, to test whether these same cytokines are also elevated in ovarian cancer-
bearing mice known to develop thrombocytosis, we quantified IL-6, TPO, and G-
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CSF levels in plasma from healthy control mice and mice bearing A2780ip2, HeyA8, 
2774, and ID8 tumors.  Plasma cytokine levels were measured using human- and 
murine-specific ELISAs in order to differentiate orthotopic human ovarian cancers 
from the murine host as the source of cytokine production.  When we tested plasma 
from our orthotopic mouse models of ovarian cancer for human IL-6, TPO, and G-
CSF, human IL-6 was significantly elevated in plasma from mice bearing A2780ip2 
(mean 6.5 ± SEM 0.8 pg/mL, p < 0.01), HeyA8 (mean 61.2 ± SEM 20.5 pg/mL, 
p<0.05), and 2774 (mean 392.5 ± SEM 86.3 pg/mL, p<0.01) tumors compared to 
healthy controls (mean 1.8 ± SEM 0.1 pg/mL).  Plasma levels of human TPO and 
G-CSF were undetectable, suggesting that the plasma compartment of these 
factors might predominantly originate from the murine host.  To determine if this 
was the case, we next used murine-specific ELISAs to evaluate plasma levels of 
TPO and G-CSF.  Murine G-CSF was significantly elevated in plasma from mice 
bearing A2780ip2 (mean 77.5 ± SEM 31.4 pg/mL, p = 0.02), HeyA8 (mean 352.9 ± 
SEM 25.8 pg/mL, p<0.01), and 2774 (mean 71.3 ± SEM 13.3 pg/mL, p<0.01) 
tumors compared to healthy controls (mean 22.8 ± SEM 4.2 pg/mL).  Plasma levels 
of murine G-CSF were also significantly increased in the syngeneic ID8 model (78.4 
± SEM 30.0 pg/mL, p = 0.02) compared to healthy C57/bl6 controls (9.5 ± SEM 1.0 
pg/mL).  Plasma levels of murine TPO were increased by 2-fold and 1.4-fold in mice 
with 2774 tumors (p < 0.05) and ID8 tumors (p < 0.01), respectively (Figure 30). 
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Figure 30.  IL-6, thrombopoietin, and G-CSF plasma levels in non-tumor 
bearing mice and mouse models of ovarian cancer.  Graphs represent results of 
ELISA-based quantification of mean IL-6, G-CSF, and TPO plasma levels ± SEM in 
non-tumor bearing mice (normal nude mice and C57/bl6 mice) and mouse models 
of ovarian cancer (A2780ip2, HeyA8, 2774, and ID8).  * indicates p < 0.01 and † 
indicates p < 0.05.     
 
      To test whether IL-6, G-CSF, and TPO are not simply associated with, but also 
play a functional role in paraneoplastic thrombocytosis, we tested the effect of 
silencing these humoral factors on thrombocytosis in A2780ip2 and 2774 orthotopic 
mouse models of ovarian cancer.  Compared to control siRNA (mean platelet count 
1405 ± 143 x 103/µL), IL-6 siRNA decreased thrombocytosis by 27% (mean platelet 
count 1297 ± 103 x 103/µL) in mice bearing A2780ip2 tumors.  TPO and G-CSF 
siRNA decreased thrombocytosis by 52% (mean platelet count 1197 ± 190 x 
103/µL) and 56% (mean platelet count 1180 ± 167 x 103/µL), respectively.  
Combination IL-6, TPO, and G-CSF siRNA was most effective and completely 
abrogated thrombocytosis in mice bearing A2780ip2 tumors (mean platelet count 
855 ± 116 x 103/µL, p = 0.02).  These data are summarized in Table 12.   
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   Table 12.  Impact of targeting IL-6, TPO, and G-CSF alone and in combination on      
   thrombocytosis in A2780ip2 orthotopic mouse model of ovarian cancer 
A2780ip2 
Treatment 
Mean Platelet Count 
(x103/µL) ± SEM 
Percent Abrogation of 
Thrombocytosis 
Control siRNA 1405 ± 143  
IL-6 siRNA 1297 ± 103 27% 
TPO siRNA 1197 ± 190 52% 
G-CSF siRNA 1180 ± 167 56% 
Combination 855 ± 116 128%* 
   * p < 0.05 
 
      In mice bearing 2774 tumors, IL-6 siRNA decreased thrombocytosis by 55% 
(mean platelet count 1776 ± 118 x 103/µL, p < 0.01) compared to control siRNA 
(mean platelet count 2724 ± 226 x 103/µL).  TPO and G-CSF siRNA decreased 
thrombocytosis by 44% (mean platelet count 1959 ± 184 x 103/µL, p = 0.03) and 
27% (mean platelet count 1893 ± 147 x 103/µL), respectively.  Compared to control 
siRNA, combination IL-6, TPO, and G-CSF siRNA abrogated thrombocytosis by 
54% (mean platelet count 1797 ± 179 x 103/µL, p = 0.01) in mice bearing 2774 
tumors.  These data are summarized in Table 13.   
   
   Table 13.  Impact of targeting IL-6, TPO, and G-CSF alone and in combination on             
   thrombocytosis in 2774 orthotopic mouse model of ovarian cancer 
2774 
Treatment 
Mean Platelet Count 
(x103/µL) ± SEM 
Percent Abrogation of 
Thrombocytosis 
Control siRNA 2724 ± 226  
IL-6 siRNA 1776 ± 118 55%* 
TPO siRNA 1959 ± 184 44%* 
G-CSF siRNA 2240 ± 187 27% 
Combination 1797 ± 179 54%* 
  * p < 0.05 
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      Given that IL-6 siRNA, TPO siRNA, and combination treatment abrogated 
thrombocytosis to similar extent, it is possible that TPO is the operative factor 
driving thrombocytosis at least in this model and that targeting TPO directly or 
indirectly via inhibition of IL-6 has the same net effect on reducing thrombocytosis.  
Platelet counts and plasma levels of IL-6 and TPO are also disproportionately 
elevated in mice with 2774 tumors compared to A2780ip2 tumor-bearing mice.  This 
might explain why we were able to completely abrogate thrombocytosis in the 
A2780ip2 model, while achieving a 50% reduction in the 2774 model.  Complete 
abrogation of thrombocytosis in the 2774 model might not have been possible with 
the dose and/or number of siRNA treatments administered in these experiments.  
Alternatively, other cytokines might contribute to thrombocytosis in the 2774 model.       
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Summary 
The present investigation makes several important contributions to our current 
understanding of the clinical implications, biological significance, and underlying 
etiology of paraneoplastic thrombocytosis.  
1)  One in three women diagnosed with epithelial ovarian cancer has 
thrombocytosis and development of this paraneoplastic syndrome is associated with 
increased risk of VTE and compromised disease specific survival.   
 
2)  Platelets are host components that can be co-opted into facilitating the growth 
and dissemination of ovarian cancer.  Functioning in this capacity, platelets increase 
tumor cell proliferation and migration, support microvessel pericytes, and promote 
tumor and endothelial cell survival.  The pro-survival effect of platelets on tumor 
cells may be a novel mechanism of chemoresistance mediated by platelet derived 
growth factor activation of tumor cell tyrosine kinase receptors such as PDGFRα.   
 
3)  Megakaryo- and thrombopoietic factors IL-6, TPO, and G-CSF produced by both 
the tumor and reciprocally by the host play a major role in the development of 
paraneoplastic thrombocytosis in ovarian carcinoma.  Targeting tumor and host 
derived TPO, IL-6, and G-CSF significantly abrogates paraneoplastic 
thrombocytosis in vivo.    
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Discussion 
Clinical implications of paraneoplastic thrombocytosis 
      Emerging clinical evidence suggests that thrombocytosis, high platelet turnover, 
and the presence of activated platelets in circulation portend poor prognosis in 
many cancers (34).  These data introduce the possibility of exploiting platelets as 
therapeutic targets for anticancer therapies.  However, the fundamental involvement 
of platelets in important physiological processes such as hemostasis complicates 
the development and implementation of anti-platelet strategies.  Moreover, our 
limited understanding of the precise mechanisms by which platelets facilitate growth 
and dissemination of malignancy has been a major hurdle in selectively blocking 
their tumor promoting activities.  A necessary first step is to identify the cancer types 
in which platelets play significant biological roles.  The current investigation provides 
both clinical and experimental evidence implicating platelets in the growth and 
progression of epithelial ovarian carcinoma.  Analysis of clinical data from over 600 
ovarian cancer patients treated at 4 centers makes this one of the largest studies of 
the prevalence and prognostic significance of thrombocytosis in oncology patients 
to date.  Our findings indicate that up to 1 in 3 women with newly diagnosed ovarian 
cancer will have platelet counts exceeding 450,000/µL.  To the best of our 
knowledge, this is the highest reported rate of paraneoplastic thrombocytosis in any 
solid malignancy, emphasizing that ovarian cancer is an exceptionally relevant 
context in which to study this process.  Rates of thrombocytosis in association with 
other solid malignancies typically range from 3-25% and this likely represents an 
overestimation, as the majority of investigators have defined thrombocytosis as a 
platelet count >400,000/uL, instead of >450,000/uL according to NHLBI criteria 
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(Table 7).  In addition to arising in a substantial proportion of ovarian cancer 
patients, thrombocytosis is associated with several aggressive clinical features 
including advanced stage disease, higher median preoperative serum CA-125 
levels, and significantly worse progression free and overall survival.  These findings 
are supported by those of Li and colleagues who identified statistically significant 
associations between thrombocytosis and advanced stage disease, high grade 
tumors, and elevated CA-125 levels in 183 patients with invasive epithelial ovarian 
and primary peritoneal carcinomas (108).  This study and a smaller investigation by 
Menczer and co-investigators also demonstrated that thrombocytosis may signify 
increased risk of suboptimal surgical cytoreduction and is an independent poor 
prognostic factor (109).  While Li and colleagues also considered the relationship 
between thrombocytosis and postoperative DVT/PE in their analysis, there was no 
discernable link, possibly due to the limited number of cases of DVT/PE in their 
cohort of patients.  To date, no other studies have examined the predictive value of 
thrombocytosis for risk of VTE in ovarian cancer.  However, the association 
between thrombosis and cancer in general is well recognized.  Existing data 
indicate that thromboembolism occurs in 4-20% of patients with malignancies and is 
the initial clinical manifestation in ~10% of patients with an occult malignancy (110-
112).  Recently, Vemulapalli et al. published their analysis of the clinical outcomes 
and factors predicting development of venous thromboembolic complications in 
Phase I patients at MDACC.  Factors predicting the development of new 
thromboembolic episodes included diagnosis of pancreatic cancer, history of 
previous venous thromboembolism, and platelet count >440,000/µL (113).  Platelet 
microthrombi formation associated with Trousseau’s syndrome is often found in 
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mucin-producing carcinomas, classically pancreatic and not uncommonly ovarian 
cancer (114).  On this basis, we preformed a predefined subset analysis to clarify 
the relationship between thrombocytosis and VTE in ovarian cancer patients.  Our 
analysis revealed that thrombocytosis significantly increases the risk of VTE in 
ovarian cancer patients and that thrombocytosis is an independent predictor of 
increased mortality in women who do develop a blood clot.  Currently, the American 
Society of Clinical Oncology guidelines recommend that all hospitalized cancer 
patients and patients undergoing major surgery for malignant disease be 
considered for pharmacologic thromboprophylaxis.  At present, routine prophylaxis 
with anticoagulation for ambulatory cancer patients is only recommended for those 
receiving thalidomide or its derivative, lenalidomide (110).  However, our findings, 
taken together with those of Vemulapalli and colleagues, suggest that instituting 
thromboprophylaxis in cancer patients with thrombocytosis might be prudent.  
Prophylaxis options could include low-dose unfractionated heparin, low-molecular-
weight heparin (LMWH), warfarin, and aspirin.  In addition to lowering the risk of 
VTE, there is growing evidence that heparins and aspirin may confer added benefit 
of anti-tumor activity, primarily by interfering with aggregation dependent platelet-
tumor cell cross-talk.  Several prospective clinical trials indicate that LMWH 
improves survival in cancer patients, and that this effect cannot be ascribed to 
prevention of VTE alone (115).  Additionally, a recent epidemiological study by 
Chan and colleagues provides compelling data that regular use of aspirin after the 
diagnosis of colorectal cancer is associated with lower risk of cancer–specific and 
overall mortality (116).  Heparins and aspirin likely have anti-neoplastic activities 
independent of their anticoagulation properties.  For example, heparin may 
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sequester growth factors released from tumor and endothelial cells away from their 
receptors and have an inhibitory effect on angiogenesis.  Additionally, heparin may 
prevent metastasis by blocking selectin- and integrin-mediated adhesion of tumor 
cells and leukocytes to endothelial cells.  Heparins also potently inhibit heparanase, 
an endo-glycosidase that facilitates tumor cell invasion through degradation and 
remodeling of the extracellular matrix (117).  The chemopreventive and tumor 
growth inhibitory effects of aspirin have largely been ascribed to inhibition of 
prostaglandin synthesis by cyclooxygenase COX-1 and COX-2 enzymes (118). 
Biological significance of paraneoplastic thrombocytosis 
      Platelets likely induce growth and progression of malignancy by diverse 
mechanisms.  Platelet adherence may shield tumor cells from immune surveillance, 
particularly from the cytotoxic activity of natural killer cells.  Direct interactions 
between platelets and tumors cells may also aid tumor cells in lodging in the 
microvasculature where they form intravascular colonies or extravasate into target 
organs.  In the tumor microenvironment, platelets release a plethora of bioactive 
factors, such as chemokines, cytokines, growth factors, and metalloproteinases, 
which are capable of promoting angiogenesis and stimulating tumor cell survival, 
proliferation, and invasion (34).  While the observational data we and others have 
generated establish strong associations between thrombocytosis and aggressive 
clinicopathologic features, they do not confirm a causal relationship between 
thrombocytosis and tumor progression.  Thus, the present investigation extends the 
current body of knowledge by providing experimental evidence for the functional 
role of platelets in driving ovarian cancer progression.  The finding that mouse 
models of ovarian cancer and other solid malignancies consistently recapitulate 
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paraneoplastic thrombocytosis served as the foundation for this work.  To illustrate 
that this is a dynamic process, we showed that platelet counts rise with increasing 
tumor burden and that platelets traffic into the tumor bed and ascites where they 
rapidly adhere to free-floating cells.  To further build a case for the supportive role of 
platelets in the development of invasive tumors, we demonstrated that halving the 
circulating platelet mass significantly inhibits tumor growth in vivo.  Histopathological 
analysis of tumors from platelet depleted mice revealed that the anti-tumor effect of 
platelet depletion was likely multi-factorial and could be attributed to decreased 
tumor cell proliferation, microvessel density, and pericyte coverage as well as 
increased tumor and endothelial cell apoptosis.  These results suggest that platelets 
can exert direct stimulatory effects on tumor cells and support angiogenesis.  To 
corroborate this, we performed in vitro studies to evaluate the impact of plasma-
purified platelets on ovarian cancer cells more definitively.  Our results reveal that 
platelets potently induce tumor cell migration, proliferation, and survival.  The finding 
that platelets can protect tumor cells from the cytotoxic insult of taxanes is 
particularly intriguing because, to the best of our knowledge, this has not been 
previously reported.  Among the potential mechanisms by which platelets may 
confer chemoresistance, one particularly logical possibility is that factors released 
by platelets, such as PDGF, activate survival signaling pathways in tumor cells.  In 
fact, PDGFRα blockade with the fully humanized antibody IMC-3G3 restored the 
cytotoxic effect of docetaxel in spite of platelets.  There is also recent evidence to 
suggest that the secretory activities of platelets stabilize the tumor vasculature and 
prevent tumor hemorrhage.  The platelet-derived factors involved in the 
maintenance of angiogenic microvessel integrity have yet to be identified.  
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Additionally, the cell type that platelets influence most is not yet known (39).  Our 
histopathological analysis of tumors resected from platelet depleted mice revealed 
lack of pericytes and disruption of endothelial-pericyte association.  Given that 
pericytes are PDGF-dependent mesenchymal cells that support and stabilize small 
blood vessels, it is possible that platelets regulate tumor vasculature homeostasis, 
in part, by nurturing pericytes.   
Mechanisms of paraneoplastic thrombocytosis 
      These data in combination with contributions from other investigations provide 
strong biological plausibility for the role of platelets in the growth and dissemination 
of cancer in general and ovarian cancer specifically.  Based on these findings, 
inhibition of paraneoplastic thrombocytosis may be an innovative approach to 
breaking the circuit between cancer cells and platelets.  Such an approach could be 
an attractive alternative to directly targeting platelets, particularly in a patient 
population heavily treated with myelosuppressive chemotherapeutic agents.  
However, to this point there have been surprisingly few studies addressing the 
mechanism of paraneoplastic thrombocytosis and thus, the underlying etiology has 
remained unknown.  An expanding body of knowledge indicates that multiple 
cytokines regulate the complex physiological process of megakaryo- and 
thrombopoiesis.  Aberrations in humoral stimuli have been the focus of intense 
investigation in patients with thrombocytopenia, but there has been less interest in 
examining such perturbations in the converse scenario of thrombocytosis.  To our 
knowledge this is the largest study examining the relationship between circulating 
levels of megakaryo- and thrombopoietic cytokines and paraneoplastic 
thrombocytosis.  Of the 10 key cytokines assayed in 150 advanced stage ovarian 
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cancer patients, IL-6, TPO, and G-CSF were significantly associated with 
thrombocytosis.  This finding is supported by several smaller reports published over 
the past 20 years.  In one study of colorectal cancer patients, significantly higher 
platelet counts and plasma TPO levels were identified in patients with stage III (n = 
10) compared to patients with stage I (n = 11) disease (119).  Elevated plasma 
granulocyte colony-stimulating factor (G-CSF) and granulocyte macrophage colony-
stimulating factor (GM-CSF) were also found to be associated with thrombocytosis 
in a case study of patients (n = 14) with a variety of solid malignancies (120).  Blay 
and colleagues demonstrated that serum IL-6 levels significantly correlate with 
platelet count in renal cell carcinoma patients (n = 100).  A small subset of patients 
with metastatic disease who participated in a phase II trial of anti-IL6 antibody (n = 
12) all experienced a reduction in platelet counts by at least 20% during treatment.  
Moreover, platelet counts normalized during anti-IL6 treatment in all patients with 
thrombocytosis upon entry into the trial (n = 5) (121).  Clinical studies examining the 
effectiveness of recombinant human IL-6 in stimulating platelet production in 
patients with advanced solid malignancies including ovarian cancer have 
demonstrated that IL-6 potently increases thrombopoiesis prior to and accelerates 
platelet recovery after chemotherapy (122, 123).  These patients also developed 
mild anemia and leukopoiesis (specifically increased neutrophils, monocytes, and 
lymphocytes).  This is of interest because the same shift in these blood count 
parameters was observed in patients with thrombocytosis in the current study.  
While we did not specifically track changes in hemoglobin and white blood cell 
counts with IL-6 levels, the strong association we uncovered between 
thrombocytosis and high IL-6 levels raises the question of whether high circulating 
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levels of IL-6 also account for mild anemia and leukocytosis in patients with 
thrombocytosis.  Taken together, these findings suggest that IL-6, TPO, and G-CSF 
may be operative humoral factors implicated in paraneoplastic thrombocytosis.  
However, these observational data are limited by their correlative nature.  
Therefore, to test whether these cytokines are not simply associated with, but also 
significantly contribute to paraneoplastic thrombocytosis, we evaluated the effect of 
siRNA-induced silencing of these cytokines alone and in combination in two 
orthotopic mouse models of ovarian cancer that characteristically develop 
paraneoplastic thrombocytosis.  The results of these in vivo experiments provide the 
first evidence of a causative role for IL-6, TPO, and G-CSF in paraneoplastic 
thrombocytosis.   
      From an experimental point of view, several issues should be addressed 
regarding the experimental protocol chosen.  Given that we targeted both human 
(tumor) and murine (host) homologs of IL-6 and TPO, we cannot determine the 
relative contribution of tumor verses host tissues to the production of these 
cytokines.  Since G-CSF was only expressed and thus silenced in the murine host 
and since targeting murine G-CSF abrogated thrombocytosis by 27-56% depending 
on the model, we can at least conclude that host tissues are a predominant and 
important source of increased circulating G-CSF.  Inflammatory stimuli such as IL-1, 
LPS, and TNF-α induce G-CSF production by macrophages, endothelial cells, 
fibroblasts and related mesenchymal cells.  At the cellular level, G-CSF induces 
proliferation of all mitogenic cells in the granulocyte lineage starting with 
uncommitted hematopoietic stem cells.  In the first phase I studies of G-CSF, G-
CSF administration resulted in mobilization of large numbers of progenitor and stem 
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cells (myeloid, erythroid, megakaryocytic) from the marrow into the peripheral blood.  
In particular, platelet recovery was markedly accelerated.  This became the basis 
for using G-CSF mobilized blood stem cells in lieu of bone marrow as the standard 
source of hematopoietic stem cells for allogenic bone marrow transplantation (124, 
125).  In keeping with these functional data, it is possible that host macrophages, 
endothelial cells, and fibroblasts increase their production of G-CSF in response to 
inflammatory stimuli part of the cancer milieu and that G-CSF in turn stimulates 
increased megakaryopoiesis from progenitors in the bone marrow.   
      Interleukin 6 is also upregulated in response to inflammatory cytokines including 
IL-1, LPS, TNF-α, and PDGF, while the IL-6 promoter is inhibited by p53.  Thus, 
overexpression of IL-6 in many malignancies could occur in response to 
inflammatory cytokines and/or as a result of p53 loss.  Given the high incidence of 
p53 mutations in epithelial ovarian cancer (23-79% of cases), the later is a distinct 
possibility (126).  An elevated serum IL-6 level has been correlated with an adverse 
prognosis in patients with several different types of malignancy, including ovarian 
cancer (127).  In vitro studies also demonstrate that ovarian cancer cell lines and 
primary ovarian tumor cultures constitutively produce IL-6 (128).  There is growing 
evidence that IL-6 can enhance hepatic TPO production, which is otherwise thought 
to occur at a constant rate.  IL-6 may also act in an autocrine fashion to increase 
TPO expression by cancer cells themselves.  IL-6 stimulation of TPO transcription 
has been reported in hepatocellular carcinoma cells (129).   The 5’-untranslated 
region of the TPO gene contains 13 segments that match the type II IL-6 response 
element consensus sequence (CTGGGA) (130).  Further, the binding of Ets family 
transcription factors to the sequence 5’-ACTTCCG-3’ in the human TPO promoter 
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has been implicated in the expression of the TPO gene in the liver.  IL-6 has been 
shown to rapidly induce DNA-binding activity to the Ets motif of the JunB promoter, 
which suggests that an Ets family transcription factor might be involved in the 
enhancement of TPO gene expression by IL-6 (129).  Here, we demonstrate 
increased TPO protein and mRNA expression in orthotopic ovarian cancers and 
livers resected from tumor-bearing mice which also have high plasma TPO levels 
and thrombocytosis.  Our in vivo data suggest that silencing TPO more effectively 
decreased thrombocytosis than silencing IL-6 in the A2780ip2 model.  In the 2774 
model, IL-6 siRNA, TPO siRNA, and combination treatment abrogated 
thrombocytosis to similar extent.  This might suggest that targeting TPO directly or 
indirectly via inhibition of IL-6 has the same net effect on reducing thrombocytosis.  
Thus, based on these observations and existing knowledge about the source and 
biological function of these cytokines, we can propose a revised hypothesis.  Tumor 
derived IL-6 stimulates host production of G-CSF and TPO which induce 
megakaryopoiesis and thrombopoiesis, respectively.  Megakaryopoiesis is 
attributed to G-CSF because of the known stimulatory effect of G-CSF on 
megakaryocyte progenitor cells and thrombopoiesis is attributed to increased TPO 
because TPO predominantly drives this process.  Tumor TPO production may also 
occur to some degree (Figure 31).   
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Figure 31.  Revised hypothesis.  Tumor derived IL-6 stimulates host production of 
G-CSF and TPO which induce megakaryopoiesis and thrombopoiesis, respectively.  
Tumor TPO production may also occur to some degree.  Megakaryopoiesis is 
attributed to G-CSF because of the known stimulatory effect of G-CSF on 
megakaryocyte progenitor cells and thrombopoiesis is attributed to increased TPO 
because TPO predominantly drives this process.   
 
      Follow-up in vivo experiments using IL-6 deficient mice would be useful for 
testing this hypothesis and for further dissecting out the relative contributions of the 
host verses tumor.  Additionally, enumeration of splenic and bone marrow 
megakaryocytes following G-CSF, IL-6, and/or TPO silencing would provide insight 
into the involvement of these targets in megakaryopoiesis verses thrombopoiesis.  
Lastly, platelet-megakaryocyte TPO receptor-mediated uptake of TPO is the 
canonical mechanism for regulating circulating TPO levels.  However, our finding 
that platelets, megakaryocytes, and plasma thrombopoietin increase concomitantly 
in patients with paraneoplastic thrombocytosis indicates that the number of 
megakaryocytes or platelets by themselves might not be the sole determinant of 
circulating TPO levels and thus thrombopoiesis.  Further, there are data to suggest 
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that mutations in the TPO receptor itself can result in decreased membrane 
expression of TPO receptor by platelets and megakaryocytes.  Thus, it is also 
possible that TPO receptor mutations or other factors leading to a decrease in cell 
surface receptor expression leads to decreased TPO clearance.   
Limitations and conclusion 
      While the current study provides new understanding of the clinical implications, 
biological significance, and underlying etiology of paraneoplastic thrombocytosis, it 
has several potential limitations.  Our clinical observations are based on a 
retrospective analysis, which has the possible associated issues of selection bias 
and incomplete data collection.  Additionally, the present analysis only takes into 
account platelet counts at the time of initial presentation.  Understanding how 
closely platelet counts track with disease status after completion of primary therapy 
could strengthen the predictive value of thrombocytosis in this and other patient 
populations.  Further, while the present study focuses on quantitative differences in 
platelet counts, other differences in platelets in the context of cancer may be equally 
important.  In particular, alterations in platelet signaling proteins and granule content 
related to active malignancy could represent a rich source of novel biomarkers and 
therapeutic targets.  These are areas that deserve much consideration particularly 
given that paraneoplastic thrombocytosis is not simply an epiphenomenon of cancer 
progression, but rather plays a central role in the complex process of malignancy.  
Blocking the development of paraneoplastic thrombocytosis and interfering with 
platelet-cancer cell interactions could represent new strategical approaches for 
improving anti-cancer therapies and patient outcomes.    
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